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ABSTRACT 
Peter Joseph Attayek: Automation of the Microraft Array Platform for the Selection of 
Cytotoxic T Lymphocytes 
(Under the Direction of Nancy L. Allbritton) 
 
Adoptive cellular therapy (ACT) is an emerging immunotherapy having significant 
promise in the treatment of a variety diseases, including cancer and chronic infections. ACT 
involves the infusion of cytotoxic T lymphocytes (CTLs) that recognize viral protein epitopes 
or, in the case of cancer, a mutated or overexpressed protein epitope present on the surface of 
diseased cells. While ACT has led to some outstanding clinical results, it is currently very 
difficult to identify and isolate highly active antigen-specific CTLs, hindering the study and 
adoption of ACT. The work described in this dissertation is focused on the automation and 
further development of the microraft array platform for the identification and isolation of CTLs 
based on cytotoxicity. 
The microraft array platform consists of an elastomeric microwell array with each 
individual microwell containing a magnetic, releasable culture site, or microraft. The microraft 
array platform enables identification of cells or cell events by image cytometry, and the 
individual microrafts can be released from the array and collected, along with the contents of 
the microraft. This technology has shown success in sorting single cells and small colonies of 
cells with high post-sort purity and viability. However, previous implementations of the 
microraft platform relied on manual identification and isolation of microrafts, limiting the 
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potential of the platform. Furthermore, the microraft array platform was only amenable to 
adherent cell types which would not enable the isolation of non-adherent CTLs. 
In this dissertation, the microraft array platform was automated and adapted for use 
with non-adherent cell types. Gelatin was used to temporarily encapsulate non-adherent cell(s) 
on a microraft without affecting viability. Image acquisition, processing and analysis software 
was written to facilitate the automated identification of cell(s) based on a variety of temporal 
fluorescence-based properties. Additionally, hardware and software were designed and 
implemented to automate the release and collection of individual microrafts. This automated 
microraft platform was used to successfully isolate antigen-specific CTLs, demonstrating its 
future potential for aiding in the study of ACT. 
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CHAPTER 1: INTRODUCTION 
1.1 Adoptive Cellular Therapy 
1.1.1 Introduction to ACT 
Adoptive cellular therapy (ACT) is an emerging immunotherapy having significant 
promise in the treatment of a variety diseases, including cancer and chronic infections.1-33 ACT 
involves the infusion of cytotoxic T lymphocytes (CTLs) that recognize viral protein epitopes 
or, in the case of cancer, a mutated or overexpressed protein epitope present on the surface of 
diseased cells (Figure 1.1).32, 34-36 When these CTLs are infused into a patient, current evidence 
suggests that the CTLs kill the diseased cells, and ideally continue to survive to provide long-
term immunological surveillance.28 Clinical trials utilizing ACT have led to outstanding results 
in some instances and a number of pharmaceutical companies are commercializing ACT.16, 36 
Although ACT has shown great promise, there are number of obstacles facing its clinical 
adoption. One such obstacle is the ability to identify and potentially expand highly active 
antigen-specific CTLs.18, 19, 22-24, 26, 37-41 
1.1.2 T cell products for ACT 
CTL populations used for ACT can be comprised of native T cells or engineered T 
cells, such as those engineered to express a particular T cell receptor (TCR) or a chimeric 
antigen receptor (CAR).36, 42 For all varieties of T cell populations, there is a necessity to first 
identify the most cytotoxic variants in order to either expand an identified native CTL or to 
identify potential TCRs or CARs for engineered T cells. The ideal CTL population for infusion 
possesses:43  
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(1) High cytotoxicity toward antigen-presenting cells 
(2) High specificity for that antigen 
(3) The ability to persist after infusion 
The focus of this dissertation is to identify CTLs and their TCR based directly on cytotoxicity, 
which will help satisfy criterion (1) stated above. Criterion (2) can be satisfied in the future by 
screening the identified candidate pool of TCRs against normal or self-antigens to determine 
the TCR with the highest specificity. Much research is currently underway to look for the ideal 
subtype of CTL that will persist in vivo to satisfy criterion (3). All of this research combined 
will help clinicians engineer and expand a highly cytotoxic, highly specific CTL population 
that is able to persist in vivo.   
A major drawback in the current standards for CTL identification is that the cells are 
not selected and cloned based directly on killing efficiency or cytotoxicity. Rather, a variety of 
surrogate markers of killing efficiency are used to isolate a mixed population of cells for 
treatment. These surrogate measures include cell proliferation in the presence of antigen-
presenting cells, the ability of a cell to produce cytokines, and the expression of a high-avidity 
TCR against an antigen on a cell’s surface.3, 15, 23, 39, 44, 45 However, recent evidence 
demonstrates that these surrogate measures are not predictive of a T cell’s cytotoxic potential. 
Indeed cytokine expression appears to be inversely correlated with tumor-cell killing, and TCR 
avidity binding is at best weakly correlated with killing ability.46-48  
1.1.3 Current standards for identification, isolation and expansion of CTLs 
Current methods to identify and isolate antigen-specific CTLs can be divided into the 
general categories of “cultivation” or “direct isolation.”49 Cultivation methods involve the 
enrichment of antigen-specific CTLs by repeatedly stimulating peripheral blood mononuclear 
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cells (PBMCs) with a cell lysate, peptide fragments, or antigen-presenting cells for many 
weeks.50-55 The cytotoxicity of the resulting enriched population can be measured by many 
techniques including chromium-51 release or flow cytometric assays; however, it is not 
possible to examine single cell cytotoxicity in order to isolate individual CTLs for expansion 
or genetic analysis. For cancer and chronic infections, enrichment can last over 10-14 weeks. 
Even after this substantial enrichment, antigen-specific CTLs typically comprise less than 1% 
of the expanded cell population, and, not uncommonly, an effective CTL population is not 
generated at all.18, 19, 23, 26, 28, 39 Additionally, this long enrichment period requires much hands 
on time and expensive reagents as the T cells are repeatedly stimulated over the weeks of 
expansion.  
Direct isolation methods utilize either human leukocyte antigen (HLA)-peptide 
multimers56, 57 or cytokine-secretion capture58-60 to label CTLs based on antigen binding 
avidity or cytokine release in response to stimulation, respectively. Subsequently, the labeled 
CTLs are isolated by fluorescence activated cell sorting (FACS) or magnetic activated cell 
sorting (MACS). These labeling and isolation techniques can be used to quickly identify and 
isolate single CTLs based on specificity or cytokine secretion; however, each has distinct 
disadvantages. Identification based on HLA-peptide multimers requires prior knowledge of the 
desired antigen and testing of a unique multimer for each antigen; this can be prohibitively 
expensive. The cytokine-secretion capture labeling method is also costly and does not reliably 
produce a high-purity CTL product.58-60 Most importantly, neither labeling technique directly 
observes physiologic cytotoxicity (i.e. CTL cytotoxicity towards an antigen-presenting cell). 
Recent research has indicated that there is little to no correlation between cytotoxicity and 
antigen avidity (HLA-peptide multimer) or cytokine secretion.46-48 As for the sorting 
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modalities, FACS can be inefficient in directing individual cells into culture wells, and cell 
viability is greatly diminished, whereas MACS is only an “enrichment” technique with a 
relatively low-purity post-sort product.61, 62 Additionally, the flow-based sorting techniques of 
FACS and MACS cannot observe the spatiotemporal characteristics needed to identify single 
cells by cytotoxicity.  
1.1.4 Microtechnologies for the identification and isolation of CTLs 
Microtechnologies possess a number of well-described advantages for cytotoxicity-
based CTL assays, including highly parallel performance, reduction in sample size and reagent 
volumes, efficient sample handling, and rapid assay performance.63-67 Several microdevices 
have been developed to screen lymphocyte function, particularly for cytokine secretion or 
enumeration of CD4+ and CD8+ lymphocytes.68-84 Devices have been developed for screening 
cytokines related to cytotoxicity, such as interferon-γ, and have been validated with both CTLs 
and natural killer (NK) cells.47, 85, 86 Unfortunately, secretion of interferon-γ and other 
cytokines are poor predictors of lymphocyte cytotoxic capacity.46-48 Direct assay of cell killing 
provides a much more stringent selection criterion to identify highly effective CTLs. Assays 
on microwell arrays have been described to characterize target cell killing by CTLs or NK 
cells, including kinetics and other parameters of cytotoxicity.46, 68-79, 87-91 These studies have 
tracked cells over time to assess heterogeneity in killing characteristics of NK and CTLs co-
cultured with their target cells.68, 87, 90-95 However, these devices were not designed for efficient 
retrieval of CTLs which is essential for ACT.  
Aspiration is the most common method for isolating individual viable cells from 
microdevices. Manual aspiration via a micromanipulator has been employed to successfully 
generate CTL clones, but this method is tedious and work-intensive.46 Several commercial 
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endeavors have commenced to develop an automated aspiration system to isolate cells; 
however, cell damage during vacuum aspiration and the potential for cross-contamination from 
aspirating non-target cells are concerns affecting the post-sort viability and purity.96 An 
alternative microwell array-based sorting method is the microraft array platform that utilizes 
the manipulation of individual superparamagnetic cell carriers by a small needle and a magnet 
to isolate individual cells or cell clusters.97-99 This sorting method does not require vacuum 
aspiration or expensive equipment and exhibits very high post-sort purity and viability; 
however, to date it has been demonstrated only for the isolation of adherent cell types.  
1.2 Microraft Arrays 
1.2.1 Fabrication of microraft arrays 
 Microraft arrays were designed to be a low-cost platform for analyzing cells in a 
microwell format with the added functionality of easy and efficient retrieval of the content 
from each well.97, 98 Microraft arrays were fabricated by first producing a template via 
photolithography (Figure 1.2 A-E). A glass slide coated with a layer of SU-8 photoresist was 
exposed to ultraviolet (UV) light through a patterned chrome mask. The chrome mask 
consisted of an array of squares with a variety of geometries (i.e. variable width of square, 
width of gap between squares and total number of elements). After UV exposure, the un-
polymerized photoresist was reacted away to leave an array of square pillars of polymerized 
SU-8 on glass. Once a template was generated, soft lithography was employed to generate a 
polydimethylsiloxane (PDMS) microwell array (Figure 1.2 F-G). The PDMS microwell array 
was then submerged in a solution of poly(styrene-co-acrylic acid) (PS-AA) in γ-butyrolactone 
(GBL) containing γFe2O3 nanoparticles. The PDMS microwell array was then pulled out 
slowly at a rate of 1 mm/min to facilitate discontinuous dewetting of the array surface, pulling 
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all solution off the walls of the microwell array while leaving a droplet within each microwell. 
The GBL solvent was evaporated at 95°C so that a hard concave PS-AA element containing 
γFe2O3 nanoparticles was left within each microwell (Figure 1.2 H-J). These elements are 
called “microrafts.” The microraft array was then glued to a polystyrene cassette with PDMS 
(Figure 1.2 K-L). 
1.2.2 Release and collection of cells on microraft arrays 
The advantage of the microraft platform over other microwell platforms is the innate 
ability to release and collect individual microrafts and therefore the cellular content within the 
microraft. Individual microrafts were released from an array by puncturing the soft PDMS 
microwell array with a small needle (10-17.5 μm tip) and pushing out the hard microraft. Once 
the needle is retracted, the elastomeric PDMS reseals, preventing medium leakage. The γFe2O3 
nanoparticles contained within the microrafts render them superparamagnetic, facilitating 
collection of individual microrafts by an external magnetic force. Prior to this dissertation, the 
microraft platform required much user interaction and was not ideal for isolating multiple 
microrafts to individual collection vessels in a single experiment. The microraft release needle 
was attached directly to the objective of an inverted microscope, and the microscope user 
manually focused the objective upwards to eject a microraft. Additionally, each microraft was 
collected by a large magnet into the lid of a Petri dish placed on top of the microraft array.98 A 
new Petri dish lid was required for each individual microraft, using substantial amounts of 
medium, reagents, dishes and time. Also, prior to this dissertation, the microraft platform was 
only amenable to isolating and collecting adherent cell types as a non-adherent cell would 
detach from the microraft during the isolation process. 
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1.2.3 Microraft automated isolation considerations 
Automation of the microraft release and collection can potentially increase throughput 
drastically, while reducing user error. The main consideration for all hardware required to 
automate the microraft isolation process was the ability to easily interface with a PC running 
MATLAB software. The microscopy equipment, including camera, motorized XY stage and 
Z-focus module, were used where applicable within the automation process. MATLAB can 
easily interface with this microscopy equipment using the open source software μManager.100, 
101 An Arduino Uno was chosen as the hub for all other automation hardware, due to its low 
cost and ability to interface easily with MATLAB. All parts for automation were designed with 
reliability and repeatability as a main focus and speed as a secondary focus. 
The motors chosen for the microraft release and collection designs were either 
servomotors or stepper motors. A servomotor uses positional feedback to create a close-looped 
system in order to control its motion and final position. Servomotors generally have a limited 
range of motion, limited by having the output shaft directly coupled to the positional feedback 
mechanism, such as a potentiometer. Conversely, a stepper motor is an open-loop system 
without positional feedback but does not suffer from limited range of motion. Servomotors 
were chosen when only a limited range of motion was required and/or accurate positional 
feedback was required. Alternatively, stepper motors were utilized whenever larger range of 
motion was needed and/or positional feedback was not necessary or acquired in other ways. 
A benchtop, 3-axis computerized numerical control (CNC) mill was used to machine 
all parts required for automation. All parts were designed to be machined from one side, as the 
3-axis mill cannot machine multiple sides. Parts requiring multiple sides to be cut were 
generally split in to multiple parts for milling and secured together after machining was 
 8  
complete. All parts were designed using SolidWorks computer-aided design (CAD) software 
and converted into g-code for the CNC mill using the HSMXpress computer-aided 
manufacturing (CAM) plugin for SolidWorks. 
1.3 Imaging and Image analysis 
1.3.1 Imaging hardware considerations 
 The ideal system for examining cytotoxicity should be able to image large fields of 
views with high fluorescence sensitivity for high throughput analysis, while maintaining 
enough resolution to identify individual cells. The Olympus MVX10 Macroview epi-
fluorescence microscope was designed for low resolution imaging with high fluorescence 
sensitivity. The microscope is equipped with 1X and 2X objectives having a high numerical 
apertures (NA) of 0.25 and 0.5, respectively. Additionally, the microscope is equipped with a 
magnification collar ranging from 0.63X to 6.3X, allowing for an effective magnification of 
0.63X-12.6X. Equation 1.1 shows the light gathering power of an epi-fluorescence 
microscope, where F is the light gathering power, M is the magnification and NA is the 
numerical aperture. 
ሺ1.1ሻ						ܨ ൌ 10ସ ൈ ቆܰܣ
ଶ
ܯ ቇ
ଶ
 
The low magnification, high NA objectives of the MVX10 Macroview microscope give it 
excellent epi-fluorescence light gathering power. Additionally, resolution is inversely 
proportional to NA, giving the objectives excellent resolution compared to other low 
magnification objectives. 
 In order to take advantage of the relatively high resolution, high fluorescence sensitivity 
and large field of view that MVX10 Macroview microscope can supply, a camera should be 
chosen with a large sensor size and number of pixels. Additionally, the camera chosen should 
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have a high quantum efficiency and low noise to take advantage of the excellent light gathering 
power of the MVX10 Macroview. The Hamamatsu ORCA-Flash4.0 boasts a 4 megapixel 
sensor with an effective area of 13.3 × 13.3 mm. The large pixel size (6.5 × 6.5 μm), peak 
quantum efficiency (82%) and median readout noise (1.0 electrons) give the ORCA-Flash4.0 
excellent sensitivity for fluorescence microscopy. Additionally, the ORCA-Flash4.0 has a 
maximum framerate of 100 fps, making it ideal for time lapse microscopy. Coupled with bright 
fluorescent dyes, the MVX10 Macroview microscope and ORCA-Flash4.0 offer excellent 
speed and sensitivity for examining CTL cytotoxicity by epi-fluorescence microscopy. 
1.3.2 Image processing and analysis 
 The development of novel methods for image processing and analysis is not a focus of 
this dissertation; however, a number of commonly used image processing and analysis methods 
are used and warrant discussion. Unless otherwise noted, the methods used in this dissertation 
are included in the MATLAB Image Processing Toolbox. In general, the image analysis 
included in this dissertation consisted of segmenting individual microrafts within an image 
prior to segmenting and analyzing cells within each microraft. Both segmentation pathways 
first consist of some type of background correction, followed by thresholding and finally a de-
clumping algorithm. 
 Due to uniquely large field of view inherent to the MVX10 Macroview microscope 
coupled with the ORCA-Flash4.0 camera, many acquired images suffer from uneven 
illumination. A well-established method for correcting uneven illumination, flat-field 
correction, was used on all bright field images prior to any type of thresholding procedure.102 
Flat-field correction divides a raw image by a “flat-field” image or illumination profile 
consisting of a single field of view without a sample present.102 The resultant image is 
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multiplied by the mean of the flat-field image to produce a corrected image as shown in 
equation 1.2 below, where C is the corrected image, R is the raw image, F is the flat-field image 
and m is the mean of the flat-field image. 
ሺ1.2ሻ						ܥ ൌ ܴܨ ൈ ݉ 
To correct for uneven illumination in fluorescence images, a different method was employed, 
known as top-hat filtering.103, 104 Top-hat filtering consists of subtracting a morphologically 
opened image from the raw image. A morphological opening is a method to remove all objects 
brighter than their surrounds that are smaller than a defined structuring element. A structuring 
element larger than the nominal size of a cell for the morphological opening is chosen so that 
when the top-hat filter is applied, most light in the image is removed other than any fluorescing 
cells. 
 Many automatic or unsupervised thresholding algorithms have been devised, each with 
their own advantages and disadvantages.105, 106 Otsu’s method, which attempts to cluster the 
pixels in an image into two or three classes by minimizing the variance of the pixel distributions 
within each class, was primarily used throughout this dissertation.107 In a bright field image, 
the curvature of individual microrafts within an array produce a dark border around each 
microraft. Otsu’s method is ideal for reliably identifying these dark borders. Combined with 
further morphological filtering, individual microrafts are easily segmented for further analysis. 
Otsu’s method also proved to be an ideal thresholding algorithm for identifying fluorescing 
cells within a fluorescence image by demarking pixels comprising the cellular fluorescence 
from the image background. However, in cases where fluorescence intensities vary from cell 
to cell, no optimal threshold value may exist that can reliably identify every cell within an 
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image without undersegmenting, or merging cells in close proximity. In these cases, an 
additional step is necessary to separate cells in close proximity. 
 The algorithm used throughout this dissertation to separate touching cells is the 
watershed algorithm, which identifies maxima in an image data that surround local minima.108-
110 The watershed transform can be implemented in a variety of ways. Within this dissertation, 
the transform is applied to either the first or second order gradient of the raw fluorescence 
image or the distance transform of the thresholded image. The first order gradient watershed 
is utilized when there is a difference in image intensity at the boundary between adjacent cells, 
the second order gradient is used when the intensity of each cell decreases as it approaches the 
cell boundary and the distance transform is utilized when fluorescent objects are of uniform 
shape and are sufficiently sparse enough so that curvature of the cell boundaries is observable 
in the thresholded image. 
 The combination of background subtraction, thresholding and watershed transform has 
proven to be sufficient for the segmentation required in this dissertation. Although many 
algorithms exist that can drastically improve upon the ability to segment individual cells in 
fluorescence images, they typically come with a significant increase in computational 
complexity and optimization. The increased complexity generally results in long analysis times 
unsuitable for identifying cytotoxicity of CTLs in real time. Various supervised and 
unsupervised methods for segmentation can achieve extremely high accuracy, but have been 
optimized for specific applications and can be challenging to implement in systems where 
cellular morphology can vary drastically from cell to cell.106, 111-121 
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1.4 Overview of this dissertation 
 The work presented in this dissertation focuses on the development of an automated 
microraft platform for the identification and isolation of antigen-specific CTLs. Chapter 2 
describes the adaptation of the microraft array platform for the isolation of non-adherent cell 
types. Additionally, it describes the development of alternative microraft release and collection 
methods that greatly increased speed and reliability and were amenable to automation. The 
work in Chapter 2 has been published in the journal Lab on a Chip.122 Chapter 3 describes the 
process of automating the microraft platform for the identification, release and collection of 
non-adherent cells. A combination of MATLAB and μManager100, 101 were used to write the 
software for microraft array image acquisition and analysis. The hardware for automated 
isolation was designed, implemented and optimized. The work in chapter 3 is in preparation to 
be submitted as a manuscript in the near future. Chapter 4 of this dissertation focuses on 
identifying antigen-specific CTLs based on cytotoxicity. A fluorescence-based cytotoxicity 
assay was performed on the microraft array platform and software was written to track 
cytotoxicity within each microraft over time. The automated isolation hardware from chapter 
3 was utilized isolate the most cytotoxic CTLs. A manuscript based on the work in chapter 4 
is in preparation to be submitted in the near future. 
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1.5 Figures 
 
Figure 1.1 Cytotoxic T lymphocyte. (A) The T cell receptor of a cytotoxic T lymphocyte 
recognizes the antigen presented on a target cell’s human leukocyte antigen. (B) The CTL 
releases cytotoxins which perforate the target cell membrane and cause the target cell to 
undergo programmed cell death, or apoptosis. (C) The CTL detaches from the dead target cell. 
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Figure 1.2 Microraft array fabrication. (A-B) A glass slide is coated with SU-8 photoresist. (C) 
The photoresist is selectively exposed to ultraviolet light through a chrome patterned mask. 
(D-E) The unexposed SU-8 is reacted away to leave SU-8 pillars on a glass substrate. (F-G) 
Soft lithography is used to create a polydimethylsiloxane microwell array. (H) The PDMS 
microwell array is dip coated in to a solution of poly(styrene-co-acrylic acid) in γ-
butyrolactone containing γFe2O3 nanoparticles. (I-J) The GBL solvent is evaporated, leaving 
hard concave microrafts within each microwell. (K) The microwell array is glued to a 
polystyrene cassette using PDMS. (L) Scanning electron micrograph of a microraft array 
containing non-adherent K562 cells. The insert shows a close up of a single microraft with the 
PDMS cut away. 
  
 15  
1.7 REFERENCES 
1. A. L. VAN DE VELDE, S. ANGUILLE AND Z. N. BERNEMAN, ACTA CLIN BELG, 
2012, 67, 399-402. 
2. J. B. BRAYER AND J. PINILLA-IBARZ, CANCER CONTROL, 2013, 49-59. 
3. A. J. BARRETT AND K. LE BLANC, CLINICAL AND EXPERIMENTAL 
IMMUNOLOGY, 2010, 161, 223-232. 
4. D. T. LE AND E. M. JAFFEE, J NATL COMPR CANC NETW, 2013, 11, 766-772. 
5. J. COUZIN-FRANKEL, SCIENCE, 2013, 340, 1514-1518. 
6. J. COUZIN-FRANKEL, SCIENCE, 2013, 342, 1432-1433. 
7. M. BLEAKLEY, C. J. TURTLE AND S. R. RIDDELL, EXPERT REVIEW OF 
HEMATOLOGY, 2012, 5, 409-425. 
8. S. A. ROSENBERG, NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8, 577-585. 
9. S. A. ROSENBERG AND M. E. DUDLEY, CURRENT OPINION IN 
IMMUNOLOGY, 2009, 21, 233-240. 
10. S. A. ROSENBERG, B. S. PACKARD, P. M. AEBERSOLD, D. SOLOMON, S. L. 
TOPALIAN, S. T. TOY, P. SIMON, M. T. LOTZE, J. C. YANG, C. A. SEIPP, C. 
SIMPSON, C. CARTER, S. BOCK, D. SCHWARTZENTRUBER, J. P. WEI AND D. 
E. WHITE, NEJM, 1988, 319, 1676-1680. 
11. S. A. ROSENBERG, N. P. RESTIFO, J. C. YANG, R. A. MORGAN AND M. E. 
DUDLEY, NATURE REVIEWS CANCER, 2008, 8, 299-308. 
12. S. A. ROSENBERG, J. C. YANG, R. M. SHERRY, U. S. KAMMULA, M. S. 
HUGHES, G. Q. PHAN, D. E. CITRIN, N. P. RESTIFO, P. F. ROBBINS, J. R. 
WUNDERLICH, K. E. MORTON, C. M. LAURENCOT, S. M. STEINBERG, D. E. 
WHITE AND M. E. DUDLEY, CLINICAL CANCER RESEARCH, 2011, 17, 4550-
4557. 
 16  
13. M. E. DUDLEY, J. R. WUNDERLICH, P. F. ROBBINS, J. C. YANG, P. HWU, D. J. 
SCHWARTZENTRUBER, S. L. TOPALIAN, R. SHERRY, N. P. RESTIFO, A. M. 
HUBICKI, M. R. ROBINSON, M. RAFFELD, P. DURAY, C. A. SEIPP, L. ROGERS-
FREEZER, K. E. MORTON, S. A. MAVROUKAKIS, D. E. WHITE AND S. A. 
ROSENBERG, SCIENCE, 2002, 298, 850-854. 
14. K. M. FRIEDMAN, L. E. DEVILLIER, S. A. FELDMAN, S. A. ROSENBERG AND 
M. E. DUDLEY, JOURNAL OF IMMUNOTHERAPY, 2011, 34, 651-661. 
15. L. GATTINONI, D. J. POWELL, S. A. ROSENBERG AND N. P. RESTIFO, 
NATURE REVIEWS IMMUNOLOGY, 2006, 6, 383-393. 
16. C. H. JUNE, JOURNAL OF CLINICAL INVESTIGATION, 2007, 117, 1466-1476. 
17. J. WEBER, M. ATKINS, P. HWU, L. RADVANYI, M. SZNOL, C. YEE AND N. C. 
I. IMMUNOTHERAPY TASK FORCE, CLINICAL CANCER RESEARCH, 2011, 17, 
1664-1673. 
18. M. KAPP, S. STEVANOVIC, K. FICK, S. M. TAN, J. LOEFFLER, A. OPITZ, T. 
TONN, G. STUHLER, H. EINSELE AND G. U. GRIGOLEIT, BONE MARROW 
TRANSPLANTATION, 2009, 43, 399-410. 
19. E. MARIJT, A. WAFELMAN, M. VAN DER HOORN, C. VAN BERGEN, R. 
BONGAERTS, S. VAN LUXEMBURG-HEIJS, J. VAN DEN MUIJSENBERG, J. O. 
WOLBERS, N. VAN DER WERFF, R. WILLEMZE AND F. FALKENBURG, 
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92, 72-80. 
20. D. L. PORTER, M. S. ROTH, S. J. LEE, C. MCGARIGLE, J. L. M. FERRARA AND 
J. H. ANTIN, BONE MARROW TRANSPLANTATION, 1996, 18, 975-980. 
21. N. P. RESTIFO, M. E. DUDLEY AND S. A. ROSENBERG, NATURE REVIEWS 
IMMUNOLOGY, 2012, 12, 269-281. 
22. E. SMITS, Z. N. BERNEMAN AND V. F. I. VAN TENDELOO, ONCOLOGIST, 
2009, 14, 240-252. 
23. R. K. ZHONG, T. A. LANE AND E. D. BALL, EXPERIMENTAL HEMATOLOGY, 
2008, 36, 486-494. 
 17  
24. T. OCHI, H. FUJIWARA AND A. YASUKAWA, JOURNAL OF BIOMEDICINE 
AND BIOTECHNOLOGY, 2010. 
25. E. L. J. SMITS, C. LEE, N. HARDWICK, S. BROOKS, V. F. I. VAN TENDELOO, 
K. ORCHARD AND B. A. GUINN, CANCER IMMUNOLOGY IMMUNOTHERAPY, 
2011, 60, 757-769. 
26. G. WEBER, J. KARBACH, S. KUCI, H. KREYENBERG, A. WILLASCH, E. 
KOSCIELNIAK, T. TONN, T. KLINGEBIEL, W. S. WELS, E. JAGER AND P. 
BADER, LEUKEMIA, 2009, 23, 1634-1642. 
27. R. J. BRENTJENS, M. L. DAVILA, I. RIVIERE, J. PARK, X. WANG, L. G. 
COWELL, S. BARTIDO, J. STEFANSKI, C. TAYLOR, M. OLSZEWSKA, O. 
BORQUEZ-OJEDA, J. QU, T. WASIELEWSKA, Q. HE, Y. BERNAL, I. V. RIJO, C. 
HEDVAT, R. KOBOS, K. CURRAN, P. STEINHERZ, J. JURCIC, T. ROSENBLAT, 
P. MASLAK, M. FRATTINI AND M. SADELAIN, SCI TRANSL MED, 2013, 5, 
177RA138. 
28. A. G. CHAPUIS, G. B. RAGNARSSON, H. N. NGUYEN, C. N. CHANEY, J. S. 
PUFNOCK, T. M. SCHMITT, N. DUERKOPP, I. M. ROBERTS, G. L. POGOSOV, 
W. Y. HO, S. OCHSENREITHER, M. WOLFL, M. BAR, J. P. RADICH, C. YEE 
AND P. D. GREENBERG, SCI TRANSL MED, 2013, 5, 174RA127. 
29. S. A. GRUPP, M. KALOS, D. BARRETT, R. APLENC, D. L. PORTER, S. R. 
RHEINGOLD, D. T. TEACHEY, A. CHEW, B. HAUCK, J. F. WRIGHT, M. C. 
MILONE, B. L. LEVINE AND C. H. JUNE, THE NEW ENGLAND JOURNAL OF 
MEDICINE, 2013, 368, 1509-1518. 
30. J. N. KOCHENDERFER, W. H. WILSON, J. E. JANIK, M. E. DUDLEY, M. 
STETLER-STEVENSON, S. A. FELDMAN, I. MARIC, M. RAFFELD, D. A. 
NATHAN, B. J. LANIER, R. A. MORGAN AND S. A. ROSENBERG, BLOOD, 
2010, 116, 4099-4102. 
31. A. J. KUMAR, E. O. HEXNER, N. V. FREY, S. M. LUGER, A. W. LOREN, R. 
RESHEF, J. BOYER, J. SMITH, E. A. STADTMAUER, B. L. LEVINE, C. H. JUNE, 
D. L. PORTER AND S. C. GOLDSTEIN, BIOL BLOOD MARROW TRANSPLANT, 
2013, 19, 1094-1101. 
32. F. LICHTENEGGER, F. M. SCHNORFEIL, W. HIDDEMANN AND M. 
SUBKLEWE, IMMUNOTHERAPY, 2013, 5, 63-78. 
 18  
33. S. L. MAUDE, N. FREY, P. A. SHAW, R. APLENC, D. M. BARRETT, N. J. BUNIN, 
A. CHEW, V. E. GONZALEZ, Z. ZHENG, S. F. LACEY, Y. D. MAHNKE, J. J. 
MELENHORST, S. R. RHEINGOLD, A. SHEN, D. T. TEACHEY, B. L. LEVINE, 
C. H. JUNE, D. L. PORTER AND S. A. GRUPP, THE NEW ENGLAND JOURNAL 
OF MEDICINE, 2014, 371, 1507-1517. 
34. O. ITZHAKI, D. LEVY, D. ZIKICH, A. J. TREVES, G. MARKEL, J. SCHACHTER 
AND M. J. BESSER, IMMUNOTHERAPY, 2013, 5, 79-90. 
35. S. GILL AND M. KALOS, TRANSL RES, 2013, 161, 365-379. 
36. C. H. JUNE, S. R. RIDDELL AND T. N. SCHUMACHER, SCIENCE 
TRANSLATIONAL MEDICINE, 2015, 7, 280PS287-280PS287. 
37. T. OCHI, H. FUJIWARA, S. OKAMOTO, J. AN, K. NAGAI, T. SHIRAKATA, J. 
MINENO, K. KUZUSHIMA, H. SHIKU AND M. YASUKAWA, BLOOD, 2011, 118, 
1495-1503. 
38. C. SMITH AND R. KHANNA, AMERICAN JOURNAL OF TRANSPLANTATION, 
2013, 13, 9-23. 
39. M. ZHANG, P. SUKHUMALCHANDRA, A. A. ENYENIHI, L. S. ST JOHN, S. A. 
HUNSUCKER, E. A. MITTENDORF, A. SERGEEVA, K. RUISAARD, Z. AL-
ATRACHE, P. A. ROPP, H. JAKHER, T. RODRIGUEZ-CRUZ, G. LIZEE, K. 
CLISE-DWYER, S. J. LU, J. J. MOLLDREM, G. L. GLISH, P. M. ARMISTEAD 
AND G. ALATRASH, CLINICAL CANCER RESEARCH, 2013, 19, 247-257. 
40. A. J. BARRETT, BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142, 877-888. 
41. M. ZHANG, P. SUKHUMALCHANDRA, A. A. ENYENIHI, L. S. ST JOHN, S. A. 
HUNSUCKER, E. A. MITTENDORF, A. SERGEEVA, K. RUISAARD, Z. AL-
ATRACHE, P. A. ROPP, H. JAKHER, T. RODRIGUEZ-CRUZ, G. LIZEE, K. 
CLISE-DWYER, S. LU, J. J. MOLLDREM, G. L. GLISH, P. M. ARMISTEAD AND 
G. ALATRASH, CLIN CANCER RES, 2013, 19, 247-257. 
42. D. F. STRONCEK, C. BERGER, M. A. CHEEVER, R. W. CHILDS, M. E. DUDLEY, 
P. FLYNN, L. GATTINONI, J. R. HEATH, M. KALOS AND F. M. MARINCOLA, 
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10, 48. 
 19  
43. S. ANGUILLE, V. F. VAN TENDELOO AND Z. N. BERNEMAN, LEUKEMIA, 
2012, 26, 2186-2196. 
44. B. J. UTTENTHAL, I. CHUA, E. C. MORRIS AND H. J. STAUSS, J GENE MED, 
2012, 14, 386-399. 
45. L. BAITSCH, S. A. FUERTES-MARRACO, A. LEGAT, C. MEYER AND D. E. 
SPEISER, TRENDS IMMUNOL, 2012, 33, 364-372. 
46. N. VARADARAJAN, B. JULG, Y. J. YAMANAKA, H. CHEN, A. O. OGUNNIYI, 
E. MCANDREW, L. C. PORTER, A. PIECHOCKA-TROCHA, B. J. HILL, D. C. 
DOUEK, F. PEREYRA, B. D. WALKER AND J. C. LOVE, J CLIN INVEST, 2011, 
121, 4322-4331. 
47. Y. J. YAMANAKA, C. T. BERGER, M. SIPS, P. C. CHENEY, G. ALTER AND J. C. 
LOVE, INTEGR BIOL (CAMB), 2012, 4, 1175-1184. 
48. S. ZHONG, K. MALECEK, L. A. JOHNSON, Z. YU, E. VEGA-SAENZ DE MIERA, 
F. DARVISHIAN, K. MCGARY, K. HUANG, J. BOYER, E. CORSE, Y. SHAO, S. 
A. ROSENBERG, N. P. RESTIFO, I. OSMAN AND M. KROGSGAARD, PROC 
NATL ACAD SCI U S A, 2013, 110, 6973-6978. 
49. A. MOOSMANN, W. HAMMERSCHMIDT AND H. J. KOLB, EUROPEAN 
JOURNAL OF CELL BIOLOGY, 2012, 91, 97-101. 
50. J. J. MELENHORST, S. R. SOLOMON, A. SHENOY, N. F. HENSEL, J. P. MCCOY, 
K. KEYVANFAR AND A. J. BARRETT, JOURNAL OF IMMUNOTHERAPY, 2006, 
29, 436-443. 
51. L. BAO, Q. SUN AND K. G. LUCAS, JOURNAL OF IMMUNOTHERAPY, 2007, 30, 
557-561. 
52. H. EINSELE, E. ROOSNEK, N. RUFER, C. SINZGER, S. RIEGLER, J. LOFFLER, 
U. GRIGOLEIT, A. MORIS, H. G. RAMMENSEE, L. KANZ, A. KLEIHAUER, F. 
FRANK, G. JAHN AND H. HEBART, BLOOD, 2002, 99, 3916-3922. 
53. K. MICKLETHWAITE, A. HANSEN, A. FOSTER, E. SNAPE, V. ANTONENAS, 
M. SARTAR, P. SHAW, K. BRADSTOCK AND D. GOTTLIEB, BIOLOGY OF 
BLOOD AND MARROW TRANSPLANTATION, 2007, 13, 707-714. 
 20  
54. A. KLEIHAUER, U. GRIGOLEIT, H. HEBART, A. MORIS, P. BROSSART, A. 
MUHM, S. STEVANOVIC, H. G. RAMMENSEE, C. SINZGER, S. RIEGLER, G. 
JAHN, L. KANZ AND H. EINSELE, BRITISH JOURNAL OF HAEMATOLOGY, 
2001, 113, 231-239. 
55. K. PEGGS, S. VERFUERTH AND S. MACKINNON, BLOOD, 2001, 97, 994-1000. 
56. M. COBBOLD, N. KHAN, B. POURGHEYSARI, S. TAURO, D. MCDONALD, H. 
OSMAN, M. ASSENMACHER, L. BILLINGHAM, C. STEWARD, C. CRAWLEY, 
E. OLAVARRIA, J. GOLDMAN, R. CHAKRAVERTY, P. MAHENDRA, C. 
CRADDOCK AND P. A. H. MOSS, JOURNAL OF EXPERIMENTAL MEDICINE, 
2005, 202, 379-386. 
57. A. SCHMITT, T. TONN, D. H. BUSCH, G. U. GRIGOLEIT, H. EINSELE, M. 
ODENDAHL, L. GERMEROTH, M. RINGHOFFER, S. RINGHOFFER, M. 
WIESNETH, J. GREINER, D. MICHEL, T. MERTENS, M. ROJEWSKI, M. MARX, 
S. VON HARSDORF, H. DOHNER, E. SEIFRIED, D. BUNJES AND M. SCHMITT, 
TRANSFUSION, 2011, 51, 591-599. 
58. K. S. PEGGS, K. THOMSON, E. SAMUEL, G. DYER, J. ARMOOGUM, R. 
CHAKRAVERTY, K. PANG, S. MACKINNON AND M. W. LOWDELL, CLINICAL 
INFECTIOUS DISEASES, 2011, 52, 49-57. 
59. P. MEIJ, I. JEDEMA, M. L. ZANDVLIET, P. L. J. VAN DER HEIDEN, M. VAN DE 
MEENT, H. M. E. VAN EGMOND, E. VAN LIEMPT, C. HOOGSTRATEN, S. 
KRUITHOF, S. VELD, E. W. A. MARIJT, P. A. VON DEM BORNE, A. C. 
LANKESTER, C. J. M. HALKES AND J. H. F. FALKENBURG, JOURNAL OF 
IMMUNOTHERAPY, 2012, 35, 621-628. 
60. T. FEUCHTINGER, K. OPHERK, W. A. BETHGE, M. S. TOPP, F. R. SCHUSTER, 
E. M. WEISSINGER, M. MOHTY, R. OR, M. MASCHAN, M. SCHUMM, K. 
HAMPRECHT, R. HANDGRETINGER, P. LANG AND H. EINSELE, BLOOD, 
2010, 116, 4360-4367. 
61. P. GUILLAUME, D. F. LEGLER, N. BOUCHERON, M. A. DOUCEY, J. C. 
CEROTTINI AND I. F. LUESCHER, J BIOL CHEM, 2003, 278, 4500-4509. 
62. P. GUILLAUME, P. BAUMGAERTNER, G. S. ANGELOV, D. SPEISER AND I. F. 
LUESCHER, J IMMUNOL, 2006, 177, 3903-3912. 
 21  
63. F. LAUTENSCHLÄGER AND M. PIEL, CURR OPIN CELL BIOL, 2013, 25, 116-
124. 
64. G. H. UNDERHILL, P. GALIE, C. S. CHEN AND S. N. BHATIA, ANNU REV CELL 
DEV BIOL, 2012, 28, 385-341. 
65. J. AUTEBERT, B. COUDERT, F. C. BIDARD, J. Y. PIERGA, S. DESCROIX, L. 
MALAQUIN AND J. L. VIOVY, METHODS, 2012, 57, 297-307. 
66. X. J. LI, A. V. VALADEZ, P. ZUO AND Z. NIE, BIOANALYSIS, 2012, 4, 1509-1525. 
67. M. L. KOVARIK, P. C. GACH, D. M. ORNOFF, Y. WANG, J. BALOWSKI, L. 
FARRAG AND N. L. ALLBRITTON, ANAL CHEM, 2012, 84, 516-540. 
68. E. FORSLUND, K. GULDEVALL, P. E. OLOFSSON, T. FRISK, A. E. 
CHRISTAKOU, M. WIKLUND AND B. ONFELT, FRONT IMMUNOL, 2012, 3, 300. 
69. J.-H. CHOI, INTERDISCIPLINARY BIO CENTRAL, 2010, 2, 1.1-1.8. 
70. E. S. DOUGLAS, S. C. HSIAO, H. ONOE, C. R. BERTOZZI, M. B. FRANCIS AND 
R. A. MATHIES, LAB CHIP, 2009, 9, 2010-2015. 
71. A. M. HIRSCH, C. A. RIVET, B. ZHANG, M. L. KEMP AND H. LU, LAB CHIP, 
2009, 9, 536-544. 
72. B. MA, G. ZHANG, J. QIN AND B. LIN, LAB CHIP, 2009, 9, 232-238. 
73. R. D. REIF, M. M. MARTINEZ, K. WANG AND D. PAPPAS, ANAL BIOANAL 
CHEM, 2009, 395, 787-795. 
74. Y. CHOI, C. YUEN, S. N. MAITI, S. OLIVARES, H. GIBBONS, H. HULS, R. 
RAPHAEL, T. C. KILLIAN, D. J. STARK, D. A. LEE, H. TORIKAI, D. 
MONTICELLO, S. S. KELLY, P. KEBRIAEI, R. E. CHAMPLIN, S. L. BISWAL 
AND L. J. COOPER, BIOMED MICRODEVICES, 2010, 12, 855-863. 
75. T. W. FRISK, M. A. KHORSHIDI, K. GULDEVALL, B. VANHERBERGHEN AND 
B. ONFELT, BIOMED MICRODEVICES, 2011, 13, 683-693. 
 22  
76. Y. QIAO AND L. MA, ANAL CHEM, 2013, 85, 6953-6957. 
77. R. D. REIF, C. AGUAS, M. M. MARTINEZ AND D. PAPPAS, ANAL BIOANAL 
CHEM, 2010, 397, 3387-3396. 
78. T. XU, W. YUE, C. W. LI, X. YAO AND M. YANG, LAB CHIP, 2013, 13, 1060-
1069. 
79. S. CHANDRASEKARAN, M. J. MCGUIRE AND M. R. KING, LAB CHIP, 2014, 14, 
118-127. 
80. X. CHENG, D. IRIMIA, M. DIXON, K. SEKINE, U. DEMIRCI, L. ZAMIR, R. G. 
TOMPKINS, W. RODRIGUEZ AND M. TONER, LAB CHIP, 2007, 7, 170-178. 
81. J. T. GOHRING AND X. FAN, PROC SPIE 2009, 7322, 12.818255. 
82. D. GAO, H.-F. LI, G.-S. GUO AND J. M. LIN, TALANTA, 2010, 82, 528-533. 
83. M. FRANKOWSKI, J. THEISEN, A. KUMMROW, P. SIMON, H. RAGUSCH, N. 
BOCK, M. SCHMIDT AND J. NEUKAMMER, SENSORS (BASEL), 2013, 13, 4674-
4693. 
84. M. POLONSKY, I. ZARETSKY AND N. FRIEDMAN, BRIEFINGS FUNCTIONAL 
GENOMICS, 2013, 12, 99-108. 
85. Y. LIU, J. YAN, M. C. HOWLAND, T. KWA AND A. REVZIN, ANAL CHEM, 2011, 
83, 8286-8292. 
86. H. ZHU, G. STYBAYEVA, M. MACAL, E. RAMANCULOV, M. D. GEORGE, S. 
DANDEKAR AND A. REVZIN, LAB CHIP, 2008, 8, 2197-2205. 
87. K. GULDEVALL, B. VANHERBERGHEN, T. FRISK, J. HURTIG, A. E. 
CHRISTAKOU, O. MANNEBERG, S. LINDSTROM, H. ANDERSSON-SVAHN, 
M. WIKLUND AND B. ONFELT, PLOS ONE, 2010, 5, E15453. 
88. E. VIVIER, D. H. RAULET, A. MORETTA, M. A. CALIGIURI, L. ZITVOGEL, L. 
L. LANIER, W. M. YOKOYAMA AND S. UGOLINI, SCIENCE, 2011, 331, 44-49. 
 23  
89. Q. HAN, N. BAGHERI, E. M. BRADSHAW, D. A. HAFLER, D. A. 
LAUFFENBURGER AND J. C. LOVE, PROC NATL ACAD SCI U S A, 2012, 109, 
1607-1612. 
90. A. MEROUANE, N. REY-VILLAMIZAR, Y. LU, I. LIADI, G. ROMAIN, J. LU, H. 
SINGH, L. J. COOPER, N. VARADARAJAN AND B. ROYSAM, 
BIOINFORMATICS, 2015, BTV355. 
91. I. LIADI, H. SINGH, G. ROMAIN, N. REY-VILLAMIZAR, A. MEROUANE, J. R. 
ADOLACION, P. KEBRIAEI, H. HULS, P. QIU AND B. ROYSAM, CANCER 
IMMUNOLOGY RESEARCH, 2015, 3, 473-482. 
92. F. L. LAI, Y. H. WANG, Y. W. CHUNG, S. M. HWANG AND L. S. HUANG, 
SENSORS (BASEL), 2011, 11, 9613-9627. 
93. A. E. CHRISTAKOU, M. OHLIN, B. VANHERBERGHEN, M. A. KHORSHIDI, N. 
KADRI, T. FRISK, M. WIKLUND AND B. ONFELT, INTEGR BIOL (CAMB), 2013, 
5, 712-719. 
94. M. A. KHORSHIDI, B. VANHERBERGHEN, J. M. KOWALEWSKI, K. R. 
GARROD, S. LINDSTROM, H. ANDERSSON-SVAHN, H. BRISMAR, M. D. 
CAHALAN AND B. ONFELT, INTEGR BIOL (CAMB), 2011, 3, 770-778. 
95. B. VANHERBERGHEN, P. E. OLOFSSON, E. FORSLUND, M. STERNBERG-
SIMON, M. A. KHORSHIDI, S. PACOURET, K. GULDEVALL, M. ENQVIST, K. 
J. MALMBERG, R. MEHR AND B. ONFELT, BLOOD, 2013, 121, 1326-1334. 
96. N. VARADARAJAN, D. S. KWON, K. M. LAW, A. O. OGUNNIYI, M. N. 
ANAHTAR, J. M. RICHTER, B. D. WALKER AND J. C. LOVE, PROCEEDINGS 
OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF 
AMERICA, 2012, 109, 3885-3890. 
97. Y. L. WANG, C. PHILLIPS, W. XU, J. H. PAI, R. DHOPESHWARKAR, C. E. SIMS 
AND N. ALLBRITTON, LAB ON A CHIP, 2010, 10, 2917-2924. 
98. P. C. GACH, Y. L. WANG, C. PHILLIPS, C. E. SIMS AND N. L. ALLBRITTON, 
BIOMICROFLUIDICS, 2011, 5. 
 24  
99. A. D. GRACZ, I. A. WILLIAMSON, K. C. ROCHE, M. J. JOHNSTON, F. WANG, 
Y. WANG, P. J. ATTAYEK, J. BALOWSKI, X. F. LIU AND R. J. LAURENZA, 
NATURE CELL BIOLOGY, 2015, 17, 340-349. 
100. A. EDELSTEIN, N. AMODAJ, K. HOOVER, R. VALE AND N. STUURMAN, 
CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 2010, 14.20. 11-14.20. 17. 
101. A. D. EDELSTEIN, M. A. TSUCHIDA, N. AMODAJ, H. PINKARD, R. D. VALE 
AND N. STUURMAN, JOURNAL OF BIOLOGICAL METHODS, 2014, 1. 
102. F. W. LEONG, M. BRADY AND J. O. D. MCGEE, JOURNAL OF CLINICAL 
PATHOLOGY, 2003, 56, 619-621. 
103. J. SERRA, IMAGE ANALYSIS AND MATHEMATICAL MORPHOLOGY, V. 1, 
ACADEMIC PRESS, 1982. 
104. P. SOILLE, MORPHOLOGICAL IMAGE ANALYSIS: PRINCIPLES AND 
APPLICATIONS, SPRINGER SCIENCE & BUSINESS MEDIA, 2013. 
105. M. SEZGIN AND B. SANKUR, JOURNAL OF ELECTRONIC IMAGING, 2004, 13, 
146-168. 
106. H. ZHANG, J. E. FRITTS AND S. A. GOLDMAN, COMPUTER VISION AND 
IMAGE UNDERSTANDING, 2008, 110, 260-280. 
107. N. OTSU, AUTOMATICA, 1975, 11, 23-27. 
108. F. MEYER, SIGNAL PROCESSING, 1994, 38, 113-125. 
109. N. MALPICA, C. DE SOLÓRZANO, J. VAQUERO, A. SANTOS, I. VALLCORBA, 
J. GARCÍA-SAGREDO AND F. DEL POZO, CYTOMETRY, 1997, 28, 289-297. 
110. H. NG, S. ONG, K. FOONG, P. GOH AND W. NOWINSKI, 2006. 
111. J. ABI-NAHED, M. P. JOLLY AND G. Z. YANG, MEDICAL IMAGE COMPUTING 
AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2006, PT 2, 2006, 4191, 1-
8. 
 25  
112. E. BENGTSSON, C. WAHLBY AND J. LINDBLAD, PATTERN RECOGNITION 
AND IMAGE ANALYSIS., 2004, 14, 157-167. 
113. N. BOUKALA, E. FAVIER, B. LAGET AND P. RADEVA, 2004. 
114. A. GARRIDO AND N. P. DE LA BLANCA, PATTERN RECOGNITION, 2000, 33, 
821-832. 
115. N. HAMILTON, TRAFFIC, 2009, 10, 951-961. 
116. K. Z. MAO, P. ZHAO AND P.-H. TAN, BIOMEDICAL ENGINEERING, IEEE 
TRANSACTIONS ON, 2006, 53, 1153-1163. 
117. E. MEIJERING, SIGNAL PROCESSING MAGAZINE, IEEE, 2012, 29, 140-145. 
118. J. RITTSCHER, ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, VOL 12, 
2010, 12, 315-344. 
119. P. RUUSUVUORI, T. AIJO, S. CHOWDHURY, C. GARMENDIA-TORRES, J. 
SELINUMMI, M. BIRBAUMER, A. M. DUDLEY, L. PELKMANS AND O. YLI-
HARJA, BMC BIOINFORMATICS, 2010, 11. 
120. K. WU, D. GAUTHIER AND M. D. LEVINE, BIOMEDICAL ENGINEERING, IEEE 
TRANSACTIONS ON, 1995, 42, 1-12. 
121. Y. J. ZHANG, PATTERN RECOGNITION, 1996, 29, 1335-1346. 
122. P. J. ATTAYEK, S. A. HUNSUCKER, Y. WANG, C. E. SIMS, P. M. ARMISTEAD 
AND N. L. ALLBRITTON, ANALYTICAL CHEMISTRY, 2015. 
 
 26  
CHAPTER 2: ARRAY-BASED PLATFORM TO SELECT, RELEASE, AND 
CAPTURE EPSTEIN–BARR VIRUS-INFECTED CELLS BASED ON 
INTERCELLULAR ADHESION 
2.1 Introduction 
By virtue of the ubiquitous requirement to isolate living cells for cloning, genetic 
analysis, and other assays, there is a need for improved techniques to collect cells displaying 
properties not amenable to selection criteria using common cell sorting techniques, for 
example, growth characteristics or cell-cell interactions. Retrieval of cells infected by the 
Epstein-Barr virus (EBV) is one such example. EBV causes infectious mononucleosis and is 
associated with a variety of tumors including nasopharyngeal carcinoma, Burkitt’s lymphoma, 
T cell lymphomas and Hodgkin’s lymphoma.1-5 The virus is highly prevalent among the human 
population, with 90% of adults having been infected at some point in their life. After initial 
infection and the establishment of an immune response, the virus enters a latent state and 
persists within the host’s cells without causing obvious host damage. There are at least 4 
different modes of EBV latency, each associated with expression of a different pattern of viral 
genes and linked to various lymphomas and lymphoproliferative disorders.3-5 Latent EBV can 
be reactivated periodically to a state of lytic replication, which is quickly controlled in 
immunocompetent adults; however, reactivation is life-threatening in immunocompromised 
populations, such as post-transplant patients and patients with acquired immunodeficiency 
syndrome (AIDS). Much remains unknown about EBV, its various latency states and 
progression to reactivation with fulminant infection. 
 27  
EBV infects both epithelial cells and B lymphocytes. B lymphocytes infected with EBV 
in vitro become immortalized and are often used as a model system to study EBV infection 
and virus-driven tumorigenesis.1 These EBV-immortalized lymphoblastoid cell lines (EBV-
LCL) recapitulate some of the behaviors of EBV-infected immune cells, including 
demonstration of features suggestive of early stage progression to "lymphoma-like" cell 
clusters.5 These clusters or groupings of cells with weak intercellular adhesion, more 
commonly known as clumps in the biology literature, are thought to arise from a single EBV-
LCL, display rapid proliferation and maintain cell-cell contact as opposed to other types of 
EBV-infected cells which lack cell-cell adhesion and clumping behavior.5-8 Clumping 
behavior characterizes these blast-like cells which display increased surface expression of 
CD23, CD39, CD40 and class II MHC, but a decrease in CD10 expression. The clumped cells 
also exhibit increased villous projections and vimentin expression.5 These characteristics 
suggest that EBV latency programs can modulate cell cycle as well as cellular adhesion. It is 
also thought that EBV-LCLs spontaneously undergo latency program switching, altering the 
proliferation, surface marker expression and intercellular adhesion of the cells in culture. 
However, the relationship between EBV gene expression, morphology and the clumping 
phenotype is not fully understood. Technologies to separate EBV-infected cells based on their 
clustering behavior would enable a pure sample of cells for analytical study to provide a better 
molecular understanding of the signaling pathways contributing to these events. 
A wide variety of cell separation technologies are available to isolate single, non-
adherent cells from a population. Fluorescence-activated cell sorting (FACS) and magnetic-
activated cell sorting (MACS) are successful commercialized methods to sort cells. In these 
techniques, cells are incubated with a fluorescently or magnetically conjugated antibody and 
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sorted based on the presence or absence of an antigens on or within the cell.9-15 FACS and 
MACS are high-throughput sorting techniques; however, both require prior knowledge of the 
antigens present to create fluorescently labelled antibodies against the desired cell 
subpopulation. Furthermore, FACS suffers from low post-sort viability while MACS suffers 
from low purity.16, 17 Microfabricated traps relying on flow for isolation, including 
mechanical18-20, optical21, 22, dielectrophoretic (DEP)23, 24 and acoustic traps25 are able to 
separate individual cells based on size, deformability or membrane capacitance. These methods 
forgo the reliance on prior knowledge of antigens and separate cells based on morphological 
characteristics; however, they are unable to segregate cell clusters from singlets. With all of 
the technologies discussed above, the pre-processing of the sample, as well as the flow forces 
inherent to each, will split apart weakly adherent cell clusters before they can be isolated. 
Furthermore, optical, acoustic and DEP-based manipulation24 require complicated and 
expensive equipment and the mechanical or electrical forces placed on the cell during 
manipulation can have a negative effect on post-sort viability.24, 26 
In recent years, technologies have been specifically designed to pick cell colonies 
grown in agar or the surface of plastic dishes by suction aspiration, e.g. Clonepix (Genetix, 
Hampshire, UK) and CellCelector (ALS Automated Lab Solutions, Jena, Germany). These 
colony picking platforms generally rely on microscopy techniques to identify individual 
colonies exhibiting a particular fluorescence signature, morphology or temporal characteristic 
before the identified cells are isolated, but are most often used for bacterial and yeast 
colonies.27-33 Another approach is laser-capture microdissection (LCM) which uses a laser to 
cut out a region of cells grown on a specialized membrane, but the technique is most 
appropriate for tissue sections of fixed cells for genetic analysis rather than isolation of live 
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cell colonies because of issues with cell viability.34, 35 Arrays of microfabricated wells to trap 
non-adherent cells followed by an analysis and pipet aspiration have been implemented by a 
number of groups to identify and isolate cells of interest.27-31 Automation of the aspiration step 
has been implemented to reduce the manpower needed for the isolation step, but cell damage 
during vacuum aspiration and the potential for cross-contamination from aspirating non-target 
cells are concerns. An alternative microwell array-based sorting method is the microraft array 
platform that utilizes the manipulation of individual superparamagnetic cell carriers by a small 
needle and a magnet to isolate individual cells or cell clusters.36-38 This sorting method does 
not require vacuum aspiration or expensive equipment and exhibits very high post-sort purity 
and viability; however, to date it has been demonstrated only for the isolation of adherent cell 
types. 
In the current work, a technique utilizing the microraft array platform is developed to 
address the need to pick single non-adherent cells or clonal clusters of non- or weakly adherent 
cells. The microraft array was originally developed by the Allbritton group as a cost effective 
means to sort cells or colonies that readily adhere to the surface of a carrier during culture on 
the array.36, 37 The microraft technology also provides an approach to track cells over time, 
enabling a broad suite of selection criteria for identifying target cells. A limitation of the 
technique is the need for the cells to be firmly adherent to the microraft carrier in order to 
release and collect the cell from the array. Here, a strategy has been developed to screen and 
then collect single, non-adherent target cells from the array, and the technique is then 
demonstrated for isolation of clonal colonies displaying only weak cell-cell interactions. To 
accomplish this isolation procedure, non-adherent cells plated on the array were encapsulated 
in a hydrogel within microwells of the array. This step served to affix the cells to the cell carrier 
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(microraft) at the base of the microwell to allow collection upon release of the microraft. A 
temperature-sensitive hydrogel formulation was optimized, and collection efficiency and cell 
viability were characterized. To efficiently release microrafts, a motorized, computer-
controlled microneedle assembly mounted on a microscope objective was developed. A small 
cylindrical device containing a movable magnet was designed to efficiently capture and deposit 
rafts into a collection vessel. This system was then used to identify and collect single and 
clumping EBV-LCLs. The utility of the method was demonstrated by assaying the expression 
of a latency-associated gene, EBV nuclear antigen 2 (EBNA2), in cells that displayed clumping 
(blasting) and non-clumping (non-blasting) behavior. 
2.2 Materials and Methods 
2.2.1 Materials 
The following materials were obtained from Sigma-Aldrich Corp. (St. Louis, MO): γ-
butyrolactone (GBL), propylene glycol monomethyl ether acetate, iron(II) chloride 
tetrahydrate, iron(III) chloride anhydrous, iron(III) nitrate nonahydrate, ammonium hydroxide 
solution, oleic acid, toluene, styrene, acrylic acid, benzoyl peroxide and gelatin from bovine 
skin (type B). SU-8 photoresist was purchased from MicroChem Corp (Newton, MA). Sylgard 
184 silicone elastomer kit (PDMS) was acquired from Dow Corning (Midland, MI). The 
following materials were procured from Life Technologies (Carlsbad, CA): RPMI 1640, fetal 
bovine serum (FBS), phosphate buffered saline (PBS), 0.05% trypsin with EDTA solution, 
penicillin/streptomycin, TaqMan Probes, TaqMan Gene Expression Assays, Superscript III 
First-Strand Synthesis System for RT-PCR, TaqMan Universal PCR Mastermix II, Hoechst 
33342, Sytox Green, CellTracker Orange CMRA and Oregon Green 488 conjugated gelatin. 
Polycarbonate and Delrin were purchased from McMaster-Carr (Elmhurst, Illinois). NdFeB 
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(Grade N52) permanent magnets were obtained from K&J Magnetics, Inc. (Plumsteadville, 
PA). Ethanol was purchased from Decon Labs (King of Prussia, PA). T4 Gene 32 Protein was 
obtained from New England Biolabs, Inc. (Ipswich, MA). PCR primers were acquired from 
Integrated DNA Technologies, Inc. (Coralville, IA). Buffer RLT, RNeasy Micro Kit and 
Carrier RNA were received from Qiagen (Hilden, Germany). All other reagents were from 
Thermo Fisher Scientific (Waltham, MA). 
2.2.2 Fabrication of microraft arrays 
PDMS microwells containing superparamagnetic, releasable polystyrene elements 
were fabricated using previously described protocols.36, 37 Briefly, a template comprised of an 
array of SU-8 pillars (200×200×200 µm, spaced 100 µm apart) on a glass slide was generated 
by standard photolithography and used to create a PDMS microwell array. A unique 4-digit 
identifier was transcribed in every 5th pillar that when transferred to the PDMS microwell 
enabled addressing of individual microrafts based on their position relative to the identifier. 
Each array contained a total of 4900 microwells (70×70 array). The PDMS microwell array 
was covered with a solution of poly(styrene-co-acrylic acid) (PS-AA) in GBL co-mixed with 
γFe2O3 nanoparticles and degassed under vacuum to remove air bubbles.37 The array was then 
lowered into a jar of the same solution and slowly pulled out by a stepper motor at a rate of 1 
mm/s. This dip-coating procedure resulted in the solution draining from the array while leaving 
a droplet of solution within each microwell. The GBL solvent was evaporated at 95°C for 12 
h producing a hard, concave polystyrene element doped with superparamagnetic nanoparticles, 
i.e. a microraft, within each microwell. The microraft array was then attached to a polystyrene 
cassette using PDMS. 
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2.2.3 Microscopy 
An Eclipse TE2000-U microscope (Nikon Instruments Inc., Melville, NY) equipped 
with Nikon CFI Plan Fluor Series objectives was used for all experiments. A CoolSNAP HQ2 
CCD camera (Photometrics, Tucson, AZ) was used for all imaging. 
2.2.4 Motorized microraft release system 
The release system consisted of two pieces of Delrin machined on a CNC mill 
(MicroMill DSLS 3000; MicroProto Systems, Chandler, AZ). One piece was designed to fit 
on to a CFI Plan Fluor 4× objective (Nikon Instruments Inc., Melville, NY) and housed a small 
stepper motor (20M020D1B; Portescap, West Chester, PA). The second Delrin component 
contained a clear polycarbonate disc with a 5 mm-long needle (150 µm base, 17.5 µm tip) 
secured to the center. The stepper motor rotated a threaded rod to translate the Delrin piece 
containing the needle linearly along the vertical axis of the objective. The clear polycarbonate 
disc permitted bright field and fluorescence microscopy with minimal distortion when the 
release system was in place. The tip of the needle was located 8.7 mm above the top surface of 
the objective. 
2.2.5 Motorized microraft release system controller 
The stepper motor was controlled using a combination of an Arduino Uno (SparkFun 
Electronics, Boulder, CO) and a motor shield (Adafruit Industries, New York, NY). The 
Arduino Uno was programmed using the open-source Arduino Software to rotate the stepper 
motor and move the needle vertically when a pushbutton was pressed. A potentiometer was 
used to adjust the travel distance of the needle (1-15 mm). 
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2.2.6 Fabrication of a magnetic microraft collection device 
A hollow polycarbonate cylinder (4.76 mm diameter, 63.5 mm length) with a 3.18 mm 
blind-end hole was machined through the center of its long axis leaving 1 mm of material at 
the blind end. The open end was tapped and closed with a nylon screw after a cylindrical 
NdFeB magnet (3.175 mm diameter, 25.4 mm length) was inserted into the cylinder. The 
magnet was able to move freely along the long axis of the cylinder as described below. The 
collection device was either held by hand or secured to a micromanipulator attached to the 
microscope stage for microraft retrieval. 
2.2.7 Cell lines, cell culture 
K562 cells, a myelogenous leukemia cell line, and EBV-infected lymphoblastoid cells 
were cultured in RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin and 100 
µg/mL streptomycin. Prior to cell culture on the microraft array, the array was oxidized in a 
plasma cleaner (Harrick Plasma, Ithaca, NY) for 5 min. The array was then rinsed once with 
100% ethanol and subsequently rinsed ×5 with PBS. The array was coated in a 0.1 wt% bovine 
gelatin in PBS and incubated at 37°C for 1 h. Before plating cells, the gelatin solution was 
aspirated and the array was rinsed ×3 with PBS. A suspension of K562 cells or EBV-LCLs 
were plated on the microraft array at various densities and the array was centrifuged at 400×g 
for 3 min. The array was then rinsed gently ×2 with medium to remove any cells that did not 
settle on to a microraft. Cells were cultured in a 37°C incubator with 5% CO2. 
2.2.8 Cell staining 
Prior to plating, cells were stained with 1 mg/mL Hoechst 33342 or 2 μM CellTracker 
Orange CMRA following manufacturer protocol. After plating, cells were incubated on the 
microraft array with 50 nM Sytox Green following the manufacturer’s protocol. 
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2.2.9 Gelatin encapsulation and fluorescent gelatin 
In those experiments isolating cells encapsulated in a hydrogel, the culture medium was 
aspirated after plating cells on microraft arrays coated with 0.1 wt% bovine gelatin, and bovine 
gelatin in PBS varying in concentration between 0 wt% and 10 wt% was added. The array was 
then incubated for 10 min at 37°C. The gelatin solution was then aspirated from the arrays 
which were placed at 4°C for 5 min to solidify the gelatin remaining within the microwells. 
Cold (4°C) culture medium was added to the arrays, which were then subjected to the cell 
isolation procedure (see below). For those experiments using fluorescent gelatin, 0.1% Oregon 
Green 488 conjugated gelatin (Life Technologies, Carlsbad, CA, 505 µL) was mixed with a 10 
wt% gelatin solution (495 µL) to generate a 5 wt% gelatin solution, which was added to the 
cell array as above. 
2.2.10 Release and collection of microrafts 
Targeted release and collection of microrafts was performed in a manner similar to that 
described previously.37 Briefly, after plating and culturing cells on an array, a microwell 
containing a cell(s) for collection was identified by microscopy. The microraft within the well 
was then expelled by piercing the PDMS substrate of the microwell array with the needle 
release device. The magnetic collection device was then placed in the media at a defined 
distance from the release site, whereupon the superparamagnetic microraft was attracted to the 
cylindrical magnet within the collection device. After capture of the microraft, the tip of the 
collection device was placed into a collection vessel such as a PCR tube or a multi-well plate 
filled with medium and placed over a block NdFeB magnet (101.6×76.2×6.35 mm) oriented 
such that the top pole of the block magnet was identical to the bottom pole of the cylindrical 
magnet within the collection device. This procedure led to the release of the captured microraft 
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into the collection well as described in the Results. In some experiments, a magnetometer 
(AlphaLab Inc., Salt Lake City, UT) was used to measure the magnetic field of each magnet 
and the magnetic field gradient (׏B) was calculated in MATLAB. In gelatin encapsulation 
experiments, the array was immersed in cold (4°C) media to maintain the hydrogel in the gelled 
state while the gelatin encapsulated cells on the microrafts were being released and collected 
on the stage of a microscope at room temperature (23°C). Released microrafts were transferred 
into warm (37°C) medium in the collection wells to melt the gelatin and release the cells. 
2.2.11 Growth rate determination 
K562 cells were seeded onto microraft arrays at a density of 0.33 cells/microraft. The 
array was either left in media or subjected to the gelatin encapsulation protocol as described 
above. Both sets of arrays were subsequently incubated at 23°C for 1 h to simulate the period 
where release and collection would take place. The arrays were then placed in a humidified, 
5% CO2 incubator at 37°C for 48 h and imaged periodically. The cell number was counted at 
each time point and the data were fit to an exponential curve to determine the doubling time of 
the cells on each array. 
2.2.12 Single-cell cloning efficiency 
The single-cell cloning efficiency of K562 cells was evaluated after successful 
collection of single cells. After collection, the single cells were cultured 3 days in culture 
medium at 37°C in a 5% CO2 incubator. The cells were imaged after the 3 day culture period 
to assess how many cells successfully proliferated. 
2.2.13 Quantitative RT-PCR 
Non-blasting cells displaying weak intercellular adhesion were also very slowly 
dividing so that they were present as singlet or doublets on rafts whereas blasting cells with 
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weak intercellular adhesion divided more rapidly with >20 cells per microraft at the time of 
analysis. For this reason microrafts with cells were collected and pooled until approximately 
20-25 cells were present for each cell phenotype for each time point for the RT-PCR 
experiments. RNA was isolated using Qiagen’s RNAeasy Micro Kit. Microrafts containing 
encapsulated cells were released and transferred to Eppendorf tubes containing 75 µL Buffer 
RLT. Carrier RNA (20 ng) was added, the samples were heated at 37°C for 1 min to melt the 
gelatin then vortexed for 1 min to homogenize the cells. The Superscript III First-Strand 
Synthesis System for RT-PCR was used to synthesize cDNA with oligo(dT) as the primer. The 
manufacturer’s protocol was followed, except that 4 µL of T4 Gene 32 Protein was added to 
each 20 µL reaction. cDNA synthesis was performed on a Veriti 96 Well Thermal Cycler 
(Applied Biosystems, Thermo Fisher Scientific, Inc., Waltham, MA). Expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was quantified using a predesigned 
assay reagent containing a 6-FAM/MGB-NFQ labeled probe (Single Tube TaqMan Gene 
Expression Assay). EBV nuclear antigen 2 (EBNA-2) was quantified by TaqMan PCR using 
forward (5’-GCTTAGCCAGTAACCCAGCACT-3’) and reverse (5’-
TGCTTAGAAGGTTGTTGGCATG-3’) primers and a TaqMan probe (5’-FAM-
CCCAACCACAGGTTCAGGCAAAACTTT-TAMRA-3’) designed by Bell et al.39 The PCR 
reactions contained 300 nM of each EBNA-2 primer and 250 nM of the EBNA-2 probe. PCR 
reactions were prepared in a final volume of 20 µL using TaqMan Universal PCR Mastermix 
II, and quantitative PCR was performed on an Applied Biosystems 7300 Real Time PCR 
System with the following thermocycling conditions: 50°C for 2 minutes to activate uracil-N 
glycosylase and 95oC for 10 min to activate AmpliTaq Gold, followed by 55 cycles of 
denaturation at 95oC for 15 s and annealing/extension at 60°C for 1 min. Experiments were 
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performed in triplicate, and no-template controls were used. Fluorescence was measured 
during the 60°C incubation in each cycle. Data was analyzed using DataAssist v3.01 Software 
(Applied Biosystems), with the maximum allowable CT set at 40 and included in the 
calculations. 
2.2.14 Statistical Analysis 
MATLAB was used for all statistical analyses. A one-way ANOVA test was performed 
to determine statistical significance between collection efficiencies and viabilities of K562 
cells isolated with the gelatin encapsulation technique. The Tukey-Kramer method was used 
to determine which groups were statistically different if the one-way ANOVA indicated a 
group was different. 
2.3 Results and Discussion 
2.3.1 Overview of hydrogel-based encapsulation and collection of cells on an array 
Initially, a strategy to screen and sort individual cells without the need for cell adhesion 
to the array elements was identified and each step optimized (Figure 2.1). Briefly, K562 cells 
(a non-adherent leukemic cell line), were cultured on an array containing superparamagnetic, 
concave microrafts (Figure 2.2) and overlaid with a liquid gelatin (Figure 2.1A-B). After 
aspiration of excess liquid from the array, the residual liquid pockets were solidified (Figure 
2.1C,E,F). 
Microrafts with cell(s) encapsulated in hydrogel were released using a motorized 
microneedle assembly (Figure 2.1D,G-J) and transferred to a multiwell plate using a magnetic 
transfer device.37 Dissolution of the gelatin then released the targeted cell(s) from the microraft 
(Figure 2.1I-L). 
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2.3.2 Impact of gelatin encapsulation on cells 
Gelatin was tested as a potential hydrogel since it is biocompatible, optically 
transparent, commonly used in cell culture, and undergoes a reversible, temperature-
dependent, liquid (4°C)-to-gel (37°C) transition. To determine if the encapsulation process 
displaced the cells during the procedure or had an untoward impact on cell viability, K562 cells 
were cultured at a density of 0.33 cells/microraft on an array so that <1 cell was present on the 
majority of microrafts. The arrays with cells were imaged, the positions of microrafts 
containing cells were recorded, and then the array was overlaid with liquid gelatin (5 wt%, 
37°C) and incubated for 10 min. Excess gelatin was aspirated and the arrays were placed at 
4°C (5 min) followed by addition of cold (4°C) medium. The microrafts were then re-imaged 
and the cell number for each microraft counted (n=405 microrafts). The majority of microrafts 
(97.8±1.1%) possessed the same number of cells before and after gelatin encapsulation, 
demonstrating that most cells remained in place during the encapsulation and gelation steps. 
Only 1.6±1.0% of microrafts had an additional cell after gelatin encapsulation. Since cells were 
seeded on the microraft array at a density of 0.33 cells/microraft, there was a 0.5±0.3% chance 
that a microraft containing a cell prior to gelatin encapsulation would be contaminated with 
another cell during encapsulation. Thus gelatin encapsulation was effective in maintaining the 
cell's location on the array. 
The effect of gelatin encapsulation on the growth rate of cells was assessed to determine 
if the encapsulation process negatively impacted cell replication, a sensitive measure of cell 
health. K562 cells were seeded and encapsulated on microraft arrays (n=3) along with 
additional arrays (n=3) on which the cells were not encapsulated as controls. Media at 4°C was 
added to both encapsulated and control arrays followed by incubation for 1 h at 23°C to 
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simulate a release and collection period. The arrays were then placed at 37°C, whereupon the 
hydrogel on the encapsulated array dissolved. The arrays were imaged at multiple time points 
over the next 48 h and the number of cells at specific sites were counted to determine the 
average doubling time of the cells under the two conditions (Figure 2.3). The data was fit to an 
exponential curve and the doubling time of the cells on each array was determined. The 
doubling time for K562 cells grown on an array after gelatin encapsulation was 18.34±0.04 h, 
which was not statistically different (p=0.28) from that on arrays not exposed to gelatin 
(19.15±0.65 h). Based on these data, encapsulation with gelatin for up to 1 h did not alter the 
subsequent growth rate of K562 cells. 
2.3.3 Motorized microraft release system 
Microrafts have previously been released by manually puncturing the PDMS microwell 
array with a needle to dislodge an individual microraft.36, 37 This method, while effective, is 
slow and labor-intensive. Additionally, the speed and duration of the manual release is user-
dependent. For these reasons, a motorized release system was designed to reduce release 
parameter variability and increase the reproducibility of the release process when paired with 
gelatin encapsulation. The system used a miniaturized motor mounted on a microscope 
objective for convenience in microscope mating. A push button actuated the needle, moving it 
at a user-determined velocity (Figure 2.4). The needle velocity was initially optimized in the 
absence of gelatin to identify the minimum time needed for microraft release. For all velocities 
tested (1, 5, 10 mm/s), targeted microrafts were released with 100±0% efficiency, and 0±0% 
of released microrafts exhibited physical damage (n=3 arrays at each speed, 10 
microrafts/array). Additionally, no untargeted microrafts were released and there was no 
observed media leakage from the PDMS at the needle puncture site. The duration of a single 
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release, including upward and downward travel of the needle, using the manual release was 
9.5±0.4 s while the motorized microraft release system set to the maximum travel speed of 10 
mm/s was 1.9±0.0 s. The motorized release system was then evaluated on a microraft array 
with gelatin-filled wells to access the impact of encapsulation on microraft release. At all 
velocities, microrafts were released with 100±0% efficiency and none (0±0%) showed physical 
damage. The motorized microraft release system was significantly faster than manual release 
(p<<0.01) and was highly efficient irrespective of the presence of a gelatin pocket above the 
raft. For all further experiments, the release system was set to a travel speed of 10 mm/s. 
2.3.4 Magnetic microraft collection device 
Microrafts containing superparamagnetic γFe2O3 nanoparticles have been collected 
manually using an external magnet after release from the array.37 This method has been ideal 
for collecting multiple microrafts into a single container; however, it has proven to be time 
consuming and labor intensive to collect individual microrafts in separate containers as would 
be needed to sort different cell populations such as blasting and non-blasting EBV-LCLs. A 
new magnetic collection system was designed to capture and precisely deposit released 
microrafts directly into arrayed collection receptacles (Figure 2.5). The magnetic transfer 
device consisted of a non-toxic polycarbonate tube containing a cylindrical magnet free to 
move within the tube (Figure 2.5A,B). To collect microrafts, the magnet was positioned at the 
tube bottom and to release a microraft the magnet in the tube was repelled upward towards the 
tube top. During microraft collection, the tube with magnet at its bottom was positioned above 
the release site in the medium overlying the microraft array to magnetically capture a released 
microraft (Figure 2.5C,D). The capture efficiency of the device was assessed at distances of 7, 
8, 9, and 10 mm between the magnet and released microrafts (Figure 2.6A). Collection with 
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and without gelatin encapsulation was assessed (3 trials, n=10 microrafts/trial). For distances 
of ≤8 mm between the surface of the array and the magnet (׏B ≥ 2.1 T/m), 100% capture 
efficiency of released microrafts was attained irrespective of gelatin encapsulation. Thus, the 
magnetic collection device did not need to be in extremely close proximity to the released 
microraft to effect capture. It is expected that a stronger magnet would enable even greater 
capture distances. 
To discharge captured microrafts from the collection device, a block magnet was 
positioned beneath the collection receptacle such that the cylindrical magnet inside the device 
was repelled by the block magnet (Figure 2.5E-H). As the device was moved over the block 
magnet, the cylindrical magnet was repelled upward within the cylinder and away from the 
captured microraft. The microraft remained attached to the tip of the collection device due to 
surface tension effects of a fluid droplet on the tip. Placing the tip of the collection device into 
the fluid in the collection vessel released the microraft from the collection device whereupon 
it was attracted by the block magnet to the bottom of the collection vessel (Figure 2.7). The 
minimum distance (maximum ׏B) between the repelled cylindrical magnet and the microraft 
on the tip of the collection device required for successful microraft transfer was measured 
(Figure 2.6B). To accomplish this study, the movement of the cylindrical magnet was 
physically restricted to specific travel distances when repelled of 1, 5, 10, 15, 20 and 30 mm 
by shortening the long axis of the hole within the cylinder (n=3 trials/distance, each with 10 
microrafts). For a release efficiency of 100%, the magnet needed to move ≥20 mm away from 
the captured microraft with a corresponding drop in the magnetic gradient to ≤0.2 T/m. Under 
these conditions, a channel length of ≥45.4 mm was needed to accommodate the length of the 
magnet and its required travel distance. A collection device with a channel length of 56.2 mm 
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was used for all further experiments. This magnetic microraft collection device also reduced 
the labor and reagents needed to isolate many microrafts into individual containers compared 
to the previous method of collection into a relatively large Petri dish lid.37 
2.3.5 Optimization of gelatin concentration for combined release, capture and deposition 
of cells 
The efficiency of combined release, capture and deposition of non-adherent cells was 
assessed using various concentrations of gelatin to encapsulate cells on individual microrafts. 
Non-adherent K562 cells were seeded on microraft arrays and the cells were encapsulated in 
either 0, 3, 5 or 10 wt% gelatin. The motorized microraft release and magnetic transfer devices 
were used to release, capture and deposit microrafts containing single K562 cells into 
individual wells of a 96-well plate containing medium at 37°C. The collection efficiency of 
single K562 cells was measured as the percentage of cells that were successfully released, 
captured, and deposited into a 96-well plate. The successfully collected single cells were 
cultured for an additional 5 days and the viability of the collected cells were determined based 
on single-cell cloning efficiency. Collection efficiencies after encapsulation with 0, 3, 5 or 10 
wt% gelatin were 25±5%, 90±7%, 100±0% and 100±0% (n = 4 arrays, 8 attempted collections 
per array), respectively. All three gelatin solutions showed a statistically significant increase 
in collection efficiency compared to the isolation attempts without gelatin (p << 0.05) while 
there was no statistical difference among the collection efficiencies of each gelatin solution (p 
= 0.14) (Figure 2.6C). The post-collection single-cell cloning efficiency after encapsulation 
and collection with 0, 3, 5 or 10 wt% gelatin solution was 100±0%, 97±3%, 96±4% and 88±8% 
(n = 4 arrays, 8 successfully collected single cells per array), respectively. Additionally, there 
was no statistically significant difference between the post-collection single-cell cloning 
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efficiency of the K562 cells using any of the solutions (p = 0.34) (Figure 2.6C). For this reason, 
a 5 wt% gelatin solution was chosen to isolate non-adherent cells in subsequent experiments. 
2.3.6 Isolation of clumping EBV-LCL cells 
Single and clumping EBV-LCLs are readily distinguished by bright field microscopy 
without the need for specialized stains due to their distinct morphologies and single-cell vs. 
clumped morphology. Thus the combination of light microscopy-based screening with a non-
traumatic, array-based sorting method was expected to enable separation of non-clumping 
(non-blasting) from clumping (blasting) lymphocytes for subsequent analyses. EBV-LCL cells 
were seeded on microraft arrays at a density of 0.33 cells/microraft. At this density 24% of 
microrafts contained single cells and 4.5% of the microrafts contained >1 cell. The EBV-LCLs 
were then cultured for 6 days on the microraft arrays. After 6 days in culture, 43.0±4.4% of 
microrafts with cells contained a single cell, while 8.4±2.7% contained clumping EBV-LCL 
colonies with ≥20 cells. The remainder of the microrafts contained colonies with <20 cells. 
The gelatin encapsulation procedure was performed on the microraft arrays and the clumping 
EBV-LCL colonies were released and collected individually into collection wells. The number 
of cells in each collected colony was re-counted post-isolation to confirm that all cells in each 
isolated colony were successfully collected (100±0%, n=3 arrays, 10 colonies per array) 
(Figure 2.8). The collected colonies were cultured for an additional 3 days, and 87±3% of the 
colonies continued to expand. These results demonstrate that proliferating cells forming 
loosely attached clusters were readily isolated with high efficiency and post-isolation viability. 
2.3.7 PCR of EBV-LCL colonies and single cells 
The expression of EBNA-2 is thought to be important for the continued survival of the 
immortalized EBV-LCL cells. EBNA-2 is expressed in only 1 of the 4 EBV latency programs 
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(latency III program) identified to date.3, 4 EBV-LCLs cultured in vitro are generally believed 
to remain in the latency III program; however, EBV infections in vivo and Burkitt’s lymphoma 
cells infected in vitro have been known to swtich between latency programs in a manner that 
is as yet poorly understood.5 We hypothesized that EBV-LCLs that do not proliferate in 
adhesive clumps may have switched latency programs which would be suggested by the down 
regulation of EBNA-2 expression. 
EBV-LCL cells were seeded and cultured on microraft arrays for 6 days. After the 
culture period, the EBV-LCLs were incubated with Sytox Green to stain dead cells. Microrafts 
containing living single cells or clumping cell clusters were identified and collected using the 
gelatin encapsulation method (Figure 2.9). In total, 3 samples of single-cell microrafts (each 
sample consisted of pooling 25 microrafts containing a single cell) and 4 samples of microrafts 
with clumped cells (each sample consisted of a single microraft with 25 clumped cells) were 
isolated for analysis. EBNA-2 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
amplified by reverse transcriptase polymerase chain reaction (RT-PCR). GAPDH was 
successfully amplified in all samples, indicating that the genetic material was effectively 
isolated from each of the samples. EBNA-2 was successfully amplified in all samples except 
1 of the non-blasting single-cell samples (Table 2.1). Expression of EBNA-2 was normalized 
to GAPDH expression to correct for the amount of genetic material collected. Normalized 
EBNA-2 expression was compared between single cells and cell clusters. There was no 
statistically significant difference in the expression of EBNA-2 between the two cell 
populations (p=0.22, Mann-Whitney test, Figure 2.10C). Analysis of a larger number of 
samples and characterization of additional viral genes in clumping vs. non-clumping cells will 
need to be performed to identify how the clumping phenotype relates to gene expression, 
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latency program, and EBV infection; nevertheless, these data demonstrate the feasibility of 
identifying and successfully isolating cells possessing a complex phenotype, weak intercellular 
adhesion, for further analysis. 
2.4 Conclusions 
We have demonstrated a method to adapt a microwell array cell separation platform to 
selectively identify and select cells based on a complex phenotype without the need for surface 
attachment all while maintaining a high post-sort purity and viability. Gelatin was used to 
temporarily capture non-adherent and loosely clustered cells within removable, concave cell 
carriers (microrafts) on the arrays. The release, capture and deposition of microrafts were 
greatly enhanced with improvements in speed and reduction in labor by employing a motorized 
collection system. The utility of the system was demonstrated by performing a sort of clumping 
EBV-LCLs that display weak cell-cell adhesion. Clonal colonies were identified and isolated 
as were non-proliferative EBV-LCL single cells for comparison by genetic analysis. 
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2.5 Figures 
 
Figure 2.1 Gelatin encapsulation. (A-D) Schematic of cell release using gelatin encapsulation. 
A) Cells were cultured on a microraft array without adhesion to the microraft surface. (B) 
Liquid gelatin was overlaid onto the array. (C) Excess liquid gelatin was aspirated from the 
array surface and the gelatin solidified. (D) Medium was placed over the solidified gelatin and 
a microraft was ejected by piercing the PDMS substrate with a needle. (E-L) Bright field (E, 
G, I, K) and fluorescence (F, H, J, L) images of the release of a single K562 cell stained with 
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CellTrace Red-Orange and encapsulated in gelatin conjugated to Oregon Green 488. Panels E 
and F are images of the array before microraft release, while panels G and H are after microraft 
release. Panel I and J are images of the collected microraft in cold medium while panels K and 
L show the cell and microraft incubation in warm medium (37°C) for 10 min. Scale bar = 200 
µm 
  
 48  
 
Figure 2.2 Microraft array. (A) Photograph of a microraft array attached to a polystyrene 
cassette. (B) Scanning electron micrograph of a microraft array containing non-adherent K562 
cells. The inset shows a single microraft. 
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Figure 2.3 Growth rate of K562 cells with (blue) and without (red) gelatin encapsulation. The 
solid lines show the fit to an exponential curve. The data points show the average of the data 
with the standard deviation. 
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Figure 2.4 Motorized microraft release. (A) Schematic of the motorized needle-release system. 
(B) Photograph of motorized microraft release device mounted on a microscope objective. (C-
D) Side view schematic of raft release with the motorized needle-release system. (E) Microraft 
array with 10 microrafts targeted (red *) for release. (F) Microraft array from panel E after 
releasing the 10 targeted microrafts. 
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Figure 2.5 Magnetic transfer system. Schematic (A) and photo (B) of the magnetic transfer 
device. The movable magnet is located at the bottom of the hollow tube. Schematic (C) and 
photo (D) of the magnetic transfer device placed over a microraft array. Schematic (E) and 
photo (F) of the magnetic transfer device after raft collection. A block magnet underneath the 
96-well plate repels the cylindrical magnet upward in the tube. A liquid droplet is present on 
the device tip securing the microraft in place. Schematic (G) and photo (H) of the magnetic 
transfer device after lowering the device into a well on the multi-well plate. 
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Figure 2.6 Efficiency of the magnetic collection device. (A) Microraft capture efficiency by 
the magnetic device as a function of the magnetic field gradient. (B) Microraft deposition 
efficiency by the magnetic device as a function of the magnetic field gradient. (C) Cell 
collection efficiency and single-cell cloning efficiency using 0, 3, 5 and 10 wt% gelatin for 
encapsulation (n=4, each consisting of 8 collection attempts). 
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Figure 2.7 Collected microrafts. Four individual microrafts released and collected in to four 
individual wells of a 96-well plate. 
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Figure 2.8 EBV-LCL collection. Bright field (A) and fluorescence (B) images of a clumping 
EBV-LCL colony on a microraft array prior to collection. Bright field (C) and fluorescence 
(D) images of the same colony after gelatin encapsulation and collection.  
Scale bar = 200 µm. 
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Figure 2.9 Flow diagram of the process used to isolate EBV-LCL colonies and single cells for 
PCR analysis. 
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Figure 2.10 Separation of blasting from non-blasting EBV-LCLs. Bright field (A) and 
fluorescence (B) image of EBV-LCLs cultured on a microraft array. A blasting EBV-LCL 
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colony and a single, non-blasting EBV-LCL cell is shown on the left and right microraft, 
respectively. (C) Expression of EBNA2 mRNA normalized to GAPDH mRNA expression (y 
axis) for blasting and non-blasting EBV-LCL subpopulations.  
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2.6 Tables 
 
Table 2.1 qRT-PCR of blasting vs. non-blasting EBV-LCLs. Data shown is an average of 3 
replicates unless otherwise indicated.  
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CHAPTER 3: GENERATION OF A CRISPR-CAS9 EDITED CELL LINE BY AN 
AUTOMATED MICRORAFT ISOLATION SYSTEM 
3.1 Introduction 
The generation of cell lines containing specific mutations is integral to the in vitro study 
of many diseases and has led to groundbreaking insights into disease pathogenesis.1-6 The most 
common mechanism for the introduction of a single base mutation in a targeted gene is the 
introduction of a double-strand break at the region of interest with homology directed repair 
(HDR) using a donor DNA sequence to insert the actual mutation. Over the past decade, several 
biomolecular reagents have been developed for the targeting of specific genomic regions and 
the creation of a double stranded DNA break at that site. Two of the first genome editing tools 
were zinc-finger nucleases (ZFNs) and transcription-activator like effector nucleases 
(TALENs).7 Both of these nucleases are composed of engineered DNA-binding domains 
coupled with a FokI nuclease. In the case of ZFNs, DNA sequence recognition is mediated by 
engineering a series of zinc-finger motifs each of which is known to bind to specific 3-4 base-
pair DNA sequences.8 For TALENs, the DNA recognition is a result of sequential TALE 
repeats that recognize repeat variable diresidues (RVDs).9 ZFNs and TALENs require protein 
engineering for each targeted double strand break, which is time consuming and expensive.7 
More recently, genome editing has been achieved using clustered regularly interspaced short 
palindromic repeat (CRISPR) sequences for DNA targeting coupled with Cas9 nuclease to 
introduce targeted double-strand DNA breaks. 
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The CRISPR-Cas9 system enables targeted genome editing in living cells, which has 
revolutionized the ability to efficiently generate disease models.10-13 While the CRISPR-Cas9 
genome editing system can be highly efficient once inside of a cell, the delivery of CRISPR-
Cas9 components to non-adherent cell types has proven to be highly variable and inefficient.14-
18 Furthermore, the CRISPR-Cas9 components are typically expressed transiently and 
heterogeneously after transfection of the CRISPR-Cas9 vector, which is usually a supercoiled 
DNA plasmid that is not replicated during cell division. Variable transfection efficiency, level 
of CRISPR-Cas9 expression, and duration of component expression can strongly affect the 
success rate of genome editing. Currently, little is known about the required duration and 
intensity of Cas9 nuclease activity required to incorporate a successful gene alteration. A 
fluorescent protein plasmid can be introduced concurrently to visualize successful transfection 
and incorporation of the CRISPR-Cas9 components; however, the transient nature of the 
CRISPR-Cas9 components and the fluorescence expression leads to difficulty in selecting 
successfully mutated cells based on a fluorescence measurement at a single time point. 
Serial dilutions or fluorescence-activated cell sorting (FACS) are the main 
methodologies used to isolated clonal cell lines with specific genomic modifications 
introduced by the CRISPR-Cas9 system.13 Serial dilutions involve diluting a sample of 
transfected cells in multiwell plates with an average density of 0.5 cells per well. This method 
is time and resource intensive and not suitable for the low transfection efficiency apparent in 
many non-adherent cell types. Furthermore, the low success rate of this method is compounded 
by low efficiency rates of HDR with the CRISPR-Cas9 system. FACS selection can be used 
when the CRISPR-Cas9 system is coupled to a fluorescent protein. Generally, cells are sorted 
based on fluorescence at 24-48 h post-transfection.13, 19, 20 However, FACS places extreme 
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stresses on sorted cells, greatly reducing their post-sort viability. Additionally, this method can 
only sort cells based on fluorescence expression at a single time point. Since the CRISPR-Cas9 
components and accompanying fluorescent marker are only transiently expressed, successfully 
transfected cells may be non-fluorescent during FACS analysis. It is predicted that multiple 
temporal fluorescence measurements will offer a much better predictor of successful genome 
editing and hence a higher yield of successfully gene-edited cells.  
Microarray devices coupled with image-based cytometry have been applied for other 
applications requiring measurement of a temporally evolving fluorescence signature in cells.21-
28 In several instances, viable cells were generally isolated by aspiration, which is very low in 
throughput, often results in cell loss and can negatively impact post isolation purity and 
viability.26, 27 As an alternative, our research group has developed microraft arrays have been 
used to isolate adherent and non-adherent cells with very high efficiency and excellent viability 
using an array platform consisting of an elastomeric microwell array with a magnetic, 
releasable culture site contained within each microwell.21, 22, 28, 29 As with other microarray 
devices, microraft arrays are compatible with measurement of fluorescence over time but also 
offer a cell retrieval method. The culture sites are readily released from the array by puncture 
of the elastomeric microwell bottom to dislodge the microraft with its accompanying cell(s). 
The magnetic culture sites with entrapped cells are then collected by an external magnet with 
minimal stress and consequently high post-sort viability.21, 22 When isolating rare populations 
of cells, such as successfully CRISPR-Cas9 gene-engineered, non-adherent cells, high post-
sort viability is essential for experimental success. Prior screening and cell sorting with the 
microraft array utilized a time-intensive manual or semi-automated system that was dependent 
on an expert user to be fully effective. Additionally, the image-based cytometry was limited to 
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manual fluorescence identification, restricting the number of cells that could be practically 
screened.  
Acute myelogenous leukemia (AML) is a desirable candidate for disease model 
generation since AML genomes have fewer mutations compared to other adult cancers.30, 31 
Recent genomic analysis has shown that a mutation in a gene involved in the RNA splicing 
machinery, an S34F mutation in the U2AF1 gene, is present in 10-15% of AML cases.30 
Additionally, this mutation in the U2AF1 gene is present in ~50% of myelodysplastic 
syndrome (MDS) cases, which is associated with a predisposition for AML.32 The generation 
of a novel cell line containing a mutated U2AF1 gene will enable the study of the mutation’s 
effect on RNA splicing, potentially leading to the discovery of mutated proteins and novel 
AML antigens for targeted treatment.  
In the current work, the microraft array platform is automated and combined with 
image processing and analysis algorithms to generate a novel myelogenous leukemia cell line 
containing a mutated U2AF1 gene for the study of AML. A myelogenous leukemia cell line 
transfected with CRISPR-Cas9 and enhanced green fluorescent protein (EGFP) was seeded on 
to a microraft array and imaged for 72 h at 12 h intervals. The duration and intensity of EGFP 
fluorescence within each microraft was analyzed and recorded for each time point. Cells 
fluorescing at any time point throughout the duration of the experiment were isolated, 
expanded and sequenced to determine if a successful mutation of the U2AF1 gene occurred. 
The fluorescence duration and intensity of the cells were examined further to glean information 
about the required Cas9 nuclease activity needed for successful genome editing. 
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3.2 Materials and Methods 
3.2.1 Materials 
Sylgard 184 silicone elastomer kit (PDMS) was acquired from Dow Corning (Midland, 
MI). Polycarbonate and Delrin were purchased from McMaster-Carr (Elmhurst, Illinois). 
Gelatin from bovine skin (type B) and γ-butyrolactone (GBL) were obtained from Sigma-
Aldrich Corp. (St. Louis, MO). SU-8 photoresist was purchased from MicroChem Corp 
(Newton, MA). NdFeB (Grade N52) permanent magnets were obtained from K&J Magnetics, 
Inc. (Plumsteadville, PA). PlasmidSafe exonuclease and QuickExtract reagent were acquired 
from Epicentre (Madison, WI).  A QIAprep spin miniprep kit and a QiaQuick PCR purification 
kit were purchased from Qiagen (Hilden, Germany). Ethanol was purchased from Decon Labs 
(King of Prussia, PA). All other reagents were from Thermo Fisher Scientific (Waltham, MA). 
3.2.2 Fabrication of microraft arrays 
Microraft arrays, consisting of PDMS microwells with releasable, magnetic elements 
or microrafts were created as described previously.21, 22, 28 Briefly, photolithography was used 
to fabricate an array of SU-8 pillars (200×200×200 µm, spaced 100 µm apart) on a glass slide 
and used as a master to generate a PDMS microwell array using soft lithography. Each PDMS 
microwell array possessed 4900 microwells (70×70 array). Each array was dip-coated into a 
solution of poly(styrene-co-acrylic acid) in GBL co-mixed with γFe2O3 nanoparticles.22 The 
array was baked at 95°C for 12 h to yield a hard, concave magnetic element, or microraft, at 
the base of each microwell. The microraft array was subsequently mounted in a polystyrene 
cassette using PDMS as a glue. 
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3.2.3 Microscopy 
An MVX10 MacroView upright microscope (Olympus, Center Valley, PA) equipped 
with an ORCA-Flash4.0 CMOS camera (Hamamatsu, Bridgewater, NJ) was used to acquire 
bright field and fluorescence images. A plan apochromat objective lens (1X with numerical 
aperture of 0.25) paired with a magnification zoom enabled a wide range of effective 
magnifications (0.63X – 6.3X) during imaging. The sample and objective movement was 
automated using PS3H122 Motorized Focus Drive and a H138A motorized XY translational 
stage (Prior Scientific Inc., Rockland, MA). A Lambda 10-3 optical filter changer positioned 
an emission filter wheel (LB10-NWE), an excitation filter wheel with SmartShutter (LB10-
NWIQ) and a stand-alone SmartShutter shutter (IQ25-SA) (Sutter Instrument, Novato, CA). A 
filter set (89000 – ET – Sedat Quad; Chroma Technology Corp, Bellows Falls, VT) with 5 
excitation bandpasses (350 ± 50 nm, 402 ± 15 nm, 490 ± 20 nm, 555 ± 25 nm, 645 ± 30 nm) 
and 4 emission bandpasses (455 ± 50 nm, 525 ± 36 nm, 605 ± 52 nm, 705 ± 72 nm) permitted 
fluorescence measurement in the blue, green, red and far red wavelengths. An arc lamp (Lumen 
200, Prior Scientific Inc., Rockland, MA) was used for illumination. All microscopy equipment 
was controlled by custom software written in MATLAB (MathWorks, Natick, MA) and used 
a Micro-Manager (Open Imaging, San Francisco, CA) core. A custom made incubator 
surrounding the microscope stage regulated temperature, humidity and CO2 concentration 
during image acquisition. 
3.2.4 Cell culture and staining 
K562 cells, a human myelogenous leukemia cell line, were used for all experiments. 
K562 cells were cultured at 37°C with 5% CO2 in RPMI 1640 supplemented with 10% fetal 
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bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco, Waltham, MA). As 
indicated, cells were stained with 1 µM calcein, AM for 30 min, washed and imaged. 
Prior to cell culture on the microraft array, the array was treated for 5 min in a plasma 
cleaner (Harrick Plasma, Ithaca, NY). The array was then washed with 100% ethanol and 
subsequently washed ×5 with phosphate-buffered saline (PBS). The microraft array was coated 
in 0.1 wt% bovine gelatin in PBS and incubated at 37°C for ≥2 h. The gelatin solution was 
aspirated and the array was washed ×3 with PBS before plating cells. Cells on the microraft 
array were cultured as described above. 
3.2.5 CRISPR-Cas9 transfection 
A CRISPR-Cas9 construct was created as previously described.13 Briefly, single guide 
RNAs (sgRNAs) were designed to target U2AF1 using the online sgRNA design tool 
(http://tools.genome-engineering.org). The sgRNA primers were designed to be (F: 
CACCGCAATAAACCGACGTTTAGCC, R: AAACGGCTAAACGTCGGTTTATTGC) 
were obtained from Integrated DNA Technologies (Coralville, IA). The single-stranded 
oligodeoxynucleotide (ssODN) was designed with 90 nucleotide homology arms 
(CCAGCAAAATAATGAGCTCTCATTTTCCCTTACAGAGTCAACTGTTCATTTTATT
TCAAAATTGGAGCATGTCGGCATGGAGACAGGTGCTTTCGGTTGCACAATAAAC
CGACATTTAGCCAGGTTTGTTTGCCTTTTTTTCATGTAAATTATAAAAACTTCATG
TTCTTTTCAAAGACAGTTAA), and was diluted to a final concentration of 10 μM. The 
ssODN was designed to introduce both a S34F mutation as well as a silent mutation adding a 
Sac1 restriction site into U2AF1.  
The sgRNA sequence was cloned into the pSpCas9-2A-GFP (px458 from Addgene, 
Cambridge, MA) vector per the manufacturer’s protocol. The reaction was treated with 
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PlasmidSafe exonuclease. The PlasmidSafe-treated plasmid was then transformed into Stellar 
competent E. coli (Clontech Laboratories, Mountain View, CA). Plasmid DNA was isolated 
with a QIAprep spin miniprep kit according to the manufacturer’s instructions. Plasmid 
sequences were verified by Sanger sequencing at the UNC Genome Analysis Facility.  
K562 cells were transfected with Fugene HD Transfection Reagent (Promega, 
Madison, WI) per manufacturer’s instructions. Briefly, K562 cells were seeded at a density of 
3 x 105 cells/mL in a 12 well tissue culture plate in culture media. Next, 500 ng/mL plasmid 
DNA and 10 nM stock of homology directed repair (HDR) template (ssODN Ultramer) were 
used per well. Cells were incubated at 37°C, 5% CO2 for 12 hours following transfection prior 
to image acquisition. 
3.2.6 Image acquisition 
Prior to imaging, the microraft array was filled with medium and a glass coverslip 
placed above the array and in contact with the medium. The flat coverslip-water interface 
eliminated the lensing due to the fluid meniscus above the array. At varying times, bright field 
and fluorescence images were acquired.  An overlap of at least 300 μm (spacing between 
microrafts + microraft width) between imaged fields of view was used in all experiments to 
insure full image coverage. For experiments to identify enhanced green fluorescent protein 
(EGFP)-expressing K562 cells, bright field and fluorescence images of the arrays were 
acquired every 12 h for 72 h. 
3.2.7 Image processing and analysis 
 A custom MATLAB program was used to process and analyze images. The microrafts 
were segmented and assigned array locations using the bright field images. Flat-field correction 
was performed on each bright field image to correct for uneven illumination intensity.33 Each 
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bright field image was thresholded using Otsu’s method and the pixels assigned a 1 or 0 based 
on their value above or below the threshold value.34 To remove debris on the arrays from 
consideration, binary images were further processed to fill the interior of each microraft border 
and objects larger than 1.5× or smaller than 0.5× the know microraft size were eliminated from 
analyses. Using this strategy, the positions of all microraft were identified at each time point 
and prior to microraft isolation. Background noise was removed from fluorescence images by 
applying a top-hat filter.35 Otsu’s method was then used to threshold each image and convert 
the image to binary.34 A watershed algorithm was applied to the binary image to separate cells 
in contact enabling the counting of fluorescent cells.36 
3.2.8 Microraft release system 
 The microraft release system was based on a previous design21, but modified for the 
current platform. The release system consisted of two Delrin components: a motor housing for 
a small stepper linear actuator (20DAM10D2U-K; 15 mm travel; Portescap, West Chester, PA) 
and a needle mount. The needle mount possessed a clear polycarbonate window with a small 
hole through which a needle (10 µm tip, 100 µm base, 5 mm long) was secured. Four stainless 
steel rods (6.35 mm diameter, 50.8 mm long) were attached to the needle mount and 4 
corresponding linear roller bearings (McMaster-Carr, Atlanta, GA) were placed into the motor 
housing to guide the needle mount as it was moved vertically by the linear actuator. The tip of 
the needle was positioned 6 mm below a microraft array prior to microraft release. The clear, 
polycarbonate window permitted bright field microscopy with the needle in place. The linear 
actuator was controlled by a custom MATLAB program interfaced to an Arduino Uno 
(SparkFun Electronics, Boulder, CO) equipped with a motor shield (Adafruit Industries, New 
York, NY). 
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3.2.9 Microraft collection wand and mount 
 A magnetic microraft collection wand was fabricated as previously described.21 
Briefly, a cylindrical NdFeB magnet (3.175 mm diameter, 25.4 mm length) was placed within 
a hollow polycarbonate cylinder (4.76 mm outer diameter, 3.18 mm inner diameter, 63.5 mm 
length).  The cylinder was blocked at both ends leaving the magnet able to move freely along 
the central axis of the cylinder. The microraft collection wand was mounted to the microscope 
objective using Delrin components and its vertical movement controlled by a linear actuator 
(L12-30-50-06-R; Firgelli Technologies Inc., Victoria, BC, Canada, travel distance of 30 mm). 
The linear actuator was controlled by a custom MATLAB program interfacing with an Arduino 
Uno equipped with a motor shield. When mounted onto the microscope, the tip of the microraft 
collection wand was located 20 mm from the surface of the microraft array. 
3.2.10 Gelatin encapsulation 
 Cells present on individual microrafts of the microraft arrays were encapsulated in 
gelatin just prior to microraft release and retrieval as described previously.21 Briefly, the culture 
medium above the array was replaced with 5 wt% bovine gelatin in PBS (37°) and the array 
was centrifuged at 400×g for 4 min. The array was then incubated for 10 min at 37°. The excess 
gelatin was aspirated from the array and the array was incubated at 4°C for 5 min to solidify 
the remaining gelatin within the microwells. Cold (4°C) culture medium was then overlaid 
onto the arrays. The microrafts with targeted cells were released and collected as described 
below. 
3.2.11 Automated microraft isolation 
 Prior to isolation, the needle location in the field of view was recorded. The X-Y-Z 
location of the microraft collection wand relative to the array was also calibrated as well as its 
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position relative to that of the wells in the 96-well plate. For microraft release a selected 
microraft was expelled from the microraft array by piercing the PDMS substrate with the 
needle using the microraft release system. The magnetic collection wand was immersed into 
the array medium attracting the released magnetic microraft. The collection wand then moved 
to and was immersed within a well of a nearby a 96-well plate containing culture medium. An 
NdFeB block magnet (101.6×76.2×6.35 mm) below the 96-well plate attracted the microraft 
into the well. The block magnet was also positioned such that the cylindrical magnet in the 
collection wand was repelled by the block magnet.21 For experiments isolating microrafts after 
gelatin encapsulation, the incubator surrounding the microscopy setup was cooled to 24°C 
prior to isolation to prevent the gelatin from liquefying. Microrafts with fluorescent cell(s) 
were identified at each time point and ranked in order based on the fluorescence intensity of 
the cells. Microrafts with the most intense fluorescence at each time point were selected for 
isolation. 
3.2.12 Post-isolation analysis 
 Following imaging, raft release and collection, cells expressing EGFP were cultured 
for an additional 7 days.  Cells (100 μL) were then transferred to a new 96 well plate. Genomic 
DNA was harvested from using QuickExtract reagent (10 μL) per well according to the 
manufacturer’s instructions. 
For polymerase chain reactions (PCR), primers were designed to flank the S34F 
mutation and surrounding homology arms with an expected PCR product of 517 bp (F: 
GCAAGGAAGAGGAGGTGCTT, R: AGGGCAGCAAATATCAGGCA). For each PCR 
reaction, 5 μL of harvested genomic DNA from the K562 cells was used. PCR was performed 
using high-fidelity Phusion DNA polymerase (New England Biolabs, Ipswich, MA) with the 
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following cycling conditions: initial denaturation 98°C for 30 seconds, denaturation 98°C for 
10 seconds, anneal 65°C for 15 seconds, extend 72°C for 15 seconds for 25 cycles.  
The PCR products were then digested using the FastDigest restriction enzyme SacI 
(Thermo Fisher Scientific, Waltham, MA) per manufacturer’s instructions. The digested PCR 
products were run on a 0.8% agarose gel to confirm the presence of the restriction site. The 
PCR products containing a SacI restriction site were then purified with the QiaQuick PCR 
purification kit and quantified using the Nanodrop 1000 and the Qubit 2.0 Fluorometer. The 
PCR products were then sequenced using Sanger sequencing by the UNC Genome Analysis 
Facility. 
3.2.13 Statistical analysis 
 A two-tailed Student T-test was used to compare microraft release efficiencies. 
MATLAB was used for all statistical analyses. 
3.3 Results and Discussion 
 While the microraft array platform has proven to be useful for isolating viable cells 
based on a variety of criteria, its full potential remains untapped since the platform possesses 
a low throughput for cell screening and separation due to the need for manual operation.21, 22, 
28, 29 Manual operation also limits the total number of cells screened and time points evaluated 
(Table 3.1) and is consequently limited largely to screens of high-frequency cells with stable 
properties over time. Automated image acquisition, analysis and cell retrieval is expected to 
permit identification of rare cells using cellular attributes at multiple time points as part of the 
selection criteria.  Since the transfection and successful mutation of K562 cells with CRISPR-
Cas9 was predicted to occur correctly in <1% of cells and to display a time-dependent 
fluorescence, automation of the microraft array platform was critical to increase the numbers 
 75  
of cells that could be assayed and retrieved in the presence of the temporally evolving 
fluorescence signature (Figure 3.1, Figure 3.2). 
3.3.1 Image acquisition and analysis 
 A customized MATLAB program was designed to control the microscope for 
automated acquisition of bright field and fluorescence images of the array at designated time 
points (Figure 3.3A). A graphical user interface (GUI) enabled user input, for example, 
fluorescence channel selection, camera exposure time, and microraft array geometry (Figure 
3.4). The MATLAB GUI required the user to manually locate and focus on the 4 corners and 
center of the microraft array. Since the elastomeric PDMS mold supporting the microrafts 
sagged in the center, the 5 identified points from each array were fit to a thin-plate spline. The 
position and focal plane for each field-of-view for the array was then interpolated from the fit 
based on the array dimensions. The spatial resolution required for image acquisition was 
optimized by considering the pixel size, array image time, microraft segmentation accuracy 
and cell identification success. Total magnification tested ranged from 2 to 6.3X with pixel 
sizes ranging from 3.17 to 1.04 µm/pixel (Table 3.2). Complete imaging of a single array in 
both bright field and fluorescence modes required 26.5 (2X) to 324 (6.3X) s. At all 
magnifications, the microrafts possessed high contrast borders under bright field illumination 
(Figure 3.3B).  After flat-field correction, thresholding and morphological filtering, nearly all 
microrafts were correctly identified in the bright field images (>99% sensitivity at all 
magnifications, Figure 3.3B-E, Table 3.2). No false positives occurred and false negatives were 
all due to debris on the microraft array. 
 Total magnification is expected to be more critical for cell segmentation than for 
microraft localization since cells are smaller than microrafts, may be in contact each other and 
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often have low contrast borders with the surrounding substrate. Since fluorescence images 
typically offer maximal contrast, K562 cells were loaded with a fluorescent dye (calcein) and 
cultured on the arrays to identify the optimal image resolution. Top-hat filtering was used to 
remove background noise and Otsu’s thresholding was used to produce a binary mask 
depicting the cell borders (Figure 3.3F-H). A watershed algorithm was then applied to separate 
cells in contact (Figure 3.3I). The microraft positions identified using the bright field image 
analysis was then used to identify and count cells on each microraft with comparison to the 
number identified manually (Table 3.2). The higher magnifications of 4X and 6.3X both 
yielded the best outcome with 0 ± 0 false negatives per microraft with a sensitivity of 100 ± 
0% for cell identification. Since arrays were imaged >3× faster at 4X relative to 6.3X, all 
subsequent experiments were performed at 4X magnification. 
3.3.2 Microraft release system 
 An automated mechanical system with customized software written in MATLAB was 
developed to release individual microrafts when supplied with a target microraft list by the 
imaging analysis software (Figure 3.5A-C). A stepper linear actuator controlled the Z position 
of a microneedle used to puncture the elastomeric PDMS array and dislodge the hard 
polystyrene microraft. The needle and motor were mounted beneath the microscope stage with 
the needle tip located 6 mm from the bottom surface of the microraft arrays. A GUI enabled 
the user to select the Z-travel distance during actuation for microraft release. The duration of 
a 7 mm needle movement (up and down) was 1.58±0.01 s (n = 288). Microrafts targeted for 
automated release were successfully dislodged with 94.8±1.6% efficiency after a single release 
attempt with the needle placed at the microraft center (n = 5 with 100 release attempts per 
trial). The efficiency was increased to 99.8±0.2% efficiency when the needle pierced the 
 77  
PDMS substrate 5 times, once at the microraft center and again at each of the four corners (n 
= 5 with 100 release attempts per trial).  Although the time for each microraft release was 
increased to 8.27±0.04 s (n = 288), the difference in the success rate was significant (p = 0.016). 
Additionally, none (0±0%) of the microrafts were physically damaged during release. When 
microrafts were overlaid with gelatin, as is required for non-adherent cell sorting on the arrays, 
the efficiency of microraft release was 85.0±8.3% and 98.0±0.4% for 1 or 5 needle actuations, 
respectively  (n = 5 with 100 release attempts per trial). Additionally no microrafts were 
observed to be damaged in these experiments. 
3.3.3 Microraft collection system 
 A motorized magnetic wand was designed to capture, transfer, and deposit the 
superparamagnetic microrafts into a collection vesicle (Figure 3.5D-F).21 To capture 
microrafts, the magnetic collection wand was placed in the medium above a microraft array 
within 2 mm of a released microraft. After 3 s, the magnetic wand was pulled out of the 
medium. Once removed from the array, the microraft was held on the wand tip by a cylindrical 
magnet within the wand as well as the surface tension of the fluid droplet on the wand tip. 
Capture of a single microraft required 13.3 ± 0.6 s (n = 288 microrafts). Microrafts were 
deposited into a 96-well plate as described previously.21  Deposition of a single microraft into 
a nearby collection receptacle (96-well plate) required 4.34±0.02 s (n = 288). Released 
microrafts with and without gelatin overlay were captured and deposited with an efficiency of 
100±0% (n = 3 per condition, 96 collection attempts per trial). The times for release, capture 
and deposition of magnetic microrafts can be decreased in the future by minimizing the travel 
distance of all components and by implementing faster actuators for the microraft release and 
collection systems. 
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3.3.4 Integrated platform performance 
 A customized MATLAB program coordinated the movement of the microraft release 
system, microraft collection system and microscope stage to isolate selected microrafts from 
the array into individual wells of a 96-well plate (Figure 3.5G). Using the GUI, the user 
initiated a microraft release, adjusting the travel distance until the needle just breaks through 
the PDMS. The user clicks on the puncture location, and the software stores the offset of the 
puncture site in relation to the XY stage position. Next the GUI allows the user to manipulate 
the XY stage and microraft collection system to place the wand tip into the 4 corners of the 
microraft array and 4 corner wells of the 96-well plate (A1, A12, H1, H12). This information 
is used to interpolate collection and deposition positions for each microraft. Microraft isolation 
consumed 35±2 s (n = 288), including microraft release (5 punches), capture, deposition and 
the stage movement between actions. The variability in isolation is largely due to the difference 
in stage movement since the wells on the 96-well plate have different physical locations (Table 
3.3). Isolation time can be decreased further in the future with a faster XY stage or alternative 
XY movement pattern for the microraft collection system. 
3.3.5 Selection of EGFP-expressing K562 cells 
 A DNA plasmid containing a U6 promotor controlling sequences leading to the 
transcription of sgRNA, Cas9 nuclease and EGFP was transfected into K562 cells along with 
a DNA HDR template containing an S34F mutation in the U2AF1 gene (Figure 3.6). The 
transfected cells were seeded on two microraft arrays 12 h after transfection. The microrafts 
were immediately imaged to identify the position of microrafts with a single cell. Microrafts 
with greater than one cell were excluded from subsequent analyses. The arrays were then 
imaged again every 12 h for a total of 72 h after transfection (Figure 3.7). Microrafts that 
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contained an EGFP-expressing cell at any time point were identified at the completion of the 
imaging time course.  A total of 24 microrafts across 2 microraft arrays possessed EGFP-
expressing cells at a minimum of 1 time point, corresponding to a transfection efficiency of 
0.75%. Most cells fluoresced with the highest intensity per cell at the 48 h and 72 h time points 
(Figure 3.8A). The median fluorescence of the EGFP-expressing cells was 0 RFU until the 48 
h time point, and the median remained >0 RFU for the 60 and 72 h time points (Figure 3.8B). 
This data indicates that if a single time point of EGFP-expression is taken, such as in FACS, it 
should be performed at the 48-72 h post-transfection. 
Microrafts with EGFP-positive cells at any time during imaging were released and 
collected using the automated microraft release platform. Of the 24 identified microrafts, 22 
were successfully isolated. The isolated cells were expanded for an additional 7 days in a 96-
well plate. A portion of each expanded colony was sequenced to determine if successful 
U2AF1 mutation incorporation occurred. Of the expanded colonies, 0% contained the U2AF1 
mutation upon Sanger sequencing. This indicated that although the CRISPR-Cas9 vector was 
successfully loaded into cells and transcribed, incorporation of the HDR template containing 
the S34F mutation of the U2AF1 gene occurred at a frequency of less than 1 in 22 (4.5%) 
plasmid-expressing cells. Due to the fact the non-adherent cells are difficult to transfect, it is 
likely that only a small fraction of K562 cells successfully transfected with the plasmid also 
receive the HDR template. Additionally, the generation of a point mutation using the CRISPR-
Cas9 system is expected to occur correctly 5-7% of the time. The low transfection rates and 
efficiency of generating point mutations using the CRISPR-Cas9 system likely mean the 
successful S34F mutation of the U2AF1 gene is <<4.5%. 
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3.4 Conclusions 
 We have demonstrated a method to screen and isolate rare cells based on temporal 
characteristics using an automated microraft array system. The automated microraft system 
was able to use image processing and analysis to quickly identify individual microrafts and 
locate fluorescent cells on those microrafts. Microrafts were identified with 99.8 ± 0.8% 
sensitivity at 4X magnification and non-adherent K562 cells stained with calcein were 
identified with a 100 ± 0% accuracy when at low densities. The low magnification enabled the 
quick and efficient scanning of microraft arrays for fluorescent events. Computer-controlled 
microraft release and collection systems were designed and implemented to enable the efficient 
isolation of individual microrafts. The microraft release system was able to release microrafts 
with 99.8 ± 0.2% and 98.0 ± 0.4% efficiency without gelatin encapsulation and with gelatin 
encapsulation, respectively. The microraft collection system demonstrated the ability to 
capture and deposit 100 ± 0% of released microrafts. The automated microraft array system 
was able to isolate microrafts at a rate of 35 ± 2 s per isolation. 
The development of the automated microraft system enables the investigation of 
complex temporal characteristics. This automated microraft array platform is ideal for the 
identification and isolation of low numbers of cells among relatively small populations (100s-
1000s of cells), it is not well suited for high volume sorting i.e. millions of cells. Each microraft 
array reported in this work had 4900 culture sites. The microraft array geometry can be scaled 
upwards to contain 105-106 of culture sites which, coupled with an incubated microscope and 
automated imaging and analysis, will facilitate high throughput screening for the identification 
of rare cell subtypes. 
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3.5 Figures 
 
Figure 3.1 Overview of the microraft array assay used to identify CRISPR-Cas9 transfected 
cells. (A) Schematic of possible experimental results from 4 microrafts imaged every 12 h after 
transfection. Cell numbers expand over time and display a time-dependent fluorescence. 
Fluorescent cells are depicted in green and non-fluorescent cells in white. (B) Simulated results 
from panel (A) showing the varying number and intensity of fluorescent cells on each microraft 
in panel A. 
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Figure 3.2 Flow diagram of automated microraft array platform used to generate a gene-
engineered U2AF1 K562 cell line. 
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Figure 3.3 Microraft image processing and analysis overview. (A) Schematic of image 
processing and analysis used to identify and isolate microrafts containing transfected K562 
cells. (B) Raw bright field image of a microraft array. (C) Bright field image of the same 
microraft array after a flat-field correction was applied. (D) Thresholding of the corrected 
image yielded a binary image marking the microraft borders. (E) Morphological filtering was 
applied to fill in the microrafts and remove any microrafts touching the image border. (F) 
Fluorescence image of two touching cells loaded with calcein. (G) A top-hat filter was applied 
to the fluorescence image to remove background noise. (H) Thresholding of the top-hat filtered 
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image yielded a binary image with the two cells connected. (I) The watershed algorithm was 
applied to separate the touching cells. 
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Figure 3.4 Graphical user interface (GUI) used to identify, release and collect microrafts. A 
pull down menu enables the user to switch between the GUI used for image acquisition (A) 
and the GUI used for microraft release and collection (B). 
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Figure 3.5 Microraft image processing and analysis overview. (A) Schematic of image 
processing and analysis used to identify and isolate microrafts containing transfected K562 
cells. (B) Raw bright field image of a microraft array. (C) Bright field image of the same 
microraft array after a flat-field correction was applied. (D) Thresholding of the corrected 
image yielded a binary image marking the microraft borders. (E) Morphological filtering was 
applied to fill in the microrafts and remove any microrafts touching the image border. (F) 
Fluorescence image of two touching cells loaded with calcein. (G) A top-hat filter was applied 
to the fluorescence image to remove background noise. (H) Thresholding of the top-hat filtered 
image yielded a binary image with the two cells connected. (I) The watershed algorithm was 
applied to separate the touching cells. 
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Figure 3.6 CRISPR-Cas9 genome editing and selection of edited cells. (A) A designed single 
guide RNA (sgRNA) binds to a specific site on the host genome. The Cas9 nuclease recognizes 
the sgRNA/DNA complex and induces a double stranded break (DSB) in the DNA. Following 
the DSB, the cell undergoes homology directed repair (HDR). Endonucleases remove 
nucleotides from both sides of the DSB, and a DNA HDR template containing the U2AF1 
mutation is inserted into the original DNA strand by homologous recombination. (B) A DNA 
plasmid containing a U6 promotor and sequences leading to the transcription of the sgRNA, 
Cas9 nuclease and enhanced green fluorescent protein (EGFP) was transfected in to K562 cells 
along with the HDR template containing the U2AF1 mutation. In some cases, the plasmid was 
not successfully transfected into the cell and did not express EGFP (i-ii). In other cases, the 
plasmid was transfected in to the cell, but either the HDR template was not transfected (iii) or 
the HDR template was not incorporated into the genome (iv). Therefore, EGFP fluorescence 
alone does not confirm mutagenesis. For a successful mutagenesis to occur, both the plasmid 
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and HDR template must be transfected into the same cell and transcription and translation must 
occur off the plasmid to produce the protein machinery needed for introduction of the mutant 
DNA (v). 
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Figure 3.7 Selection of EGFP-expressing K562 cells. (A) Selected example of EGFP 
expression on a microraft over a 72 h period.  The top row of images was acquired by bright 
field microscopy and the lower panel by fluorescence microscopy. (B) Cell fluorescence 
normalized to cell area and number of cells for the microraft shown in panel (A).  
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Figure 3.8 K562 transfection results. (A) Histogram showing the number of microrafts 
containing cells that exhibited their peak EGFP expression per cell at each measured time point 
(n = 76). (B) For all microrafts that contained an EGFP-expressing cell at any time point, the 
average fluorescence of the cells on the microraft are shown for each time point. Each point 
represents a single microraft and the lines represent the median. 
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3.6 Tables 
 
Table 3.1 Advantages of automated microraft analysis and isolation compared to manual 
analysis and isolation. 
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Table 3.2 Comparison of 2X, 4X and 6.3X magnification. 
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Table 3.3 Mean microraft isolation time for each well of a 96-well plate. Each row and column 
represent a single well of a 96-well plate (i.e. Row C, Column 3 represents well C3). Wells 
further from the microraft array take a longer time for successful isolation. 
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CHAPTER 4: IDENTIFICATION AND ISOLATION OF ANTIGEN-SPECIFIC 
CYTOTOXIC T LYMPHOCYTES WITH AN AUTOMATED MICRORAFT 
SORTING SYSTEM 
4.1 Introduction 
Antigen-specific, cytotoxic CD8+ T cell responses are an essential component in the 
adaptive immune system’s ability to control both viral infections and cancer. Multiple types of 
experiments designed to quantify the number of antigen-specific CD8+ T cells and measure the 
cytotoxic activity of a T cell population are routinely used to characterize CD8+ responses; 
however, many standard immune monitoring assays have limitations with respect to sample 
size (or cell number) requirements, sample processing, or cost that make detailed 
characterization of immune responses problematic.  
To measure the fraction of antigen-specific CD8+ T cells in a T cell population, which 
is important in measuring immune responses and immunodominance in vivo as well as in the 
expansion of antigen-specific T cells in culture, peptide/MHC tetramers are often used.1, 2 
Tetramer-based enumeration is expensive however, requiring a unique tetramer per antigen to 
be tested. Furthermore, this modality, by itself, does not provide a measurement of T cell 
effector function or activity. For functional assessment of individual T cells in a bulk 
population, intracellular cytokine flow cytometry3, which can be coupled with tetramer 
enumeration4-7, or ELISPOT analysis can be employed.8, 9 These methods result in the 
measurement of cytokine secretion in response to a stimulus, such as TCR binding to its 
cognate peptide/MHC; however, these approaches cannot measure individual T cell mediated 
killing, the most significant property of CD8+ T cells. In addition, once an evaluation of 
 100  
individual T cell function is performed using cytokine secretion techniques, the interrogated T 
cells are not viable or amenable to further characterization or expansion.  
Beyond the quantification of antigen-specific T cells and measurements of their 
function, there is often a need for clonal expansion of individual T cells to allow further 
characterization or to produce clonal populations that can be used as probes for monitoring 
antigen presentation under different situations and in different cell types. Clonal T cell 
populations can be expanded using limiting dilution methods and by fluorescence activated 
cell sorting (FACS); however, both methods have drawbacks. Limiting dilution has no 
selection method so, while it is often a more efficient method for clonal T cell expansion 
compared to FACS, many expanded clonal populations do not have the antigen-specific 
properties of interest.10-12 FACS can provide specific cell sorting based upon the expression of 
cell surface markers, including TCRs specific to peptide/MHC tetramers13, 14; however, cell 
viability is affected by the temperature and pressures applied to the T cells in the cell sorter 
and the enhanced activation of Src kinases through ligation of the TCR with multimeric 
peptide/MHC complexes.15, 16 
In this project we have developed a methodology to identify, isolate and clonally 
expand antigen specific CD8+ T cells based upon their killing of antigen expressing target cells. 
The methodology was developed using microraft arrays with each microraft designed to 
contain a population of fluorescently labeled antigen-presenting target cells with 1 CD8+ T 
cell. A cytotoxicity dye in the media allowed for the measurement of target cell death over 
time. Microrafts that contained a CD8+ T cell and showed a high rate of target cell death were 
transferred from the array to a well in a 96-well plate using a previously designed needle-
release device, and the sorted T cells were clonally expanded for further characterization 
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including measurement of TCR affinity to a peptide/MHC tetramer and sequencing of the 
TCRα and TCRβ CDR3 regions. 
4.2 Materials and Methods 
4.2.1 Materials 
The following materials were obtained from Sigma-Aldrich Corp. (St. Louis, MO): γ-
butyrolactone (GBL), propylene glycol monomethyl ether acetate, iron(II) chloride 
tetrahydrate, iron(III) chloride anhydrous, iron(III) nitrate nonahydrate, ammonium hydroxide 
solution, oleic acid, toluene, styrene, acrylic acid, benzoyl peroxide, gelatin from bovine skin 
(type B), dimethyl sulfoxide (DMSO) and 4’,6-diamidino-2-phenylindole dihydrochloride 
(DAPI). SU-8 photoresist was purchased from MicroChem Corp (Newton, MA). Sylgard 184 
silicone elastomer kit (PDMS) was acquired from Dow Corning (Midland, MI). Polycarbonate 
and Delrin were purchased from McMaster-Carr (Elmhurst, Illinois). NdFeB (Grade N52) 
permanent magnets were obtained from K&J Magnetics, Inc. (Plumsteadville, PA). Ethanol 
was purchased from Decon Labs (King of Prussia, PA). The following items were obtained 
from Thermo Fisher Scientific (Waltham, MA): Dulbecco’s phosphate buffered saline (DPBS) 
(Gibco), CTS AIM V media (Gibco), CellTrace Far Red DDAO-SE (Molecular Probes), Cell 
Tracker Green CMFDA (5-chloromethylfluorescein diacetate; Molecular Probes), 
LIVE/DEAD Fixable Violet Dead Cell Stain (Molecular Probes), SuperScript III One-Step 
RT-PCR System with Platinum Taq High Fidelity DNA Polymerase (Life Technologies), 
nuclease-free water (Ambion) and RNase Inhibitor (Ambion). Ficoll-Paque PLUS was from 
GE Healthcare (Little Chalfont, United Kingdom) and Lymphoprep was from Axis-Shield PoC 
AS (Oslo, Norway).   Interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 (IL-6), 
interleukin-7 (IL-7), interleukin-15 (IL-15), interleukin-21 (IL-21), Fms-related tyrosine 
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kinase 3 ligand (Flt3-ligand), stem cell factor (SCF) and tumor necrosis factor alpha (TNF-α) 
were purchased from Peprotech.  Granulocyte-macrophage colony stimulating factor (GM-
CSF; Leukine®) was from Sanofi (Paris, France) and interferon alpha (IFN-α; Intron® A) was 
from Schering Corporation (Kenilworth, NJ). GemCell Human Serum AB was purchased from 
Gemini Bio-Products (West Sacramento, CA). Purified anti-human CD3 antibody (OKT3 
clone) was purchased from eBioscience, Inc. (San Diego, CA). Costar 6 and 24 well ultra-low 
attachment plates as well as all tissue culture flasks were manufactured by Corning, Inc. 
(Corning, NY). MACS BSA Stock Solution, CD34 Microbead Kit UltraPure human, CD8+ T 
cell Isolation Kit, autoMACS rinsing solution, preseparation filters and columns for magnetic 
separation were purchased from Miltenyi Biotec (Auburn, CA). PE-Cy7-anti-CD8, FITC-anti-
CD4, FITC-anti-CD14, FITC-anti-CD16 and FITC-anti-CD19 antibodies were purchased 
from BD Biosciences (Franklin Lakes, NJ). APC-labeled influenza M1 tetramer and APC 
labeled negative tetramer were purchased from MBL International (Woburn, MA). The 
influenza M1 peptide (M1p, GILGFVFTL) was synthesized by Peptide 2.0 (Chantilly, VA), 
and the PR1 peptide (PR1, VLQELNVTV) was synthesized by Bio-Synthesis, Inc. 
(Lewisville, TX). Ten percent ultrapure methanol-free formaldehyde was purchased from 
Polysciences, Inc. (Warrington, PA). The RNeasy Micro Kit, OneStep RT-PCR Kit and PCR 
Purification Kit were purchased from Qiagen (Hilden, Germany).  The Fast Start High Fidelity 
PCR System was purchased from Roche Diagnostics (Basel, Switzerland). All other reagents 
were from Thermo Fisher Scientific (Waltham, MA). 
4.2.2 Fabrication of microraft arrays 
Microraft arrays, consisting of PDMS microwells containing releasable, magnetic 
elements were created using previously described methods.17-19 Briefly, photolithography was 
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used to fabricate an array of SU-8 pillars (200 × 200 × 200 µm, spaced 100 µm apart) on a 
glass slide and used as a template to generate a PDMS microwell array. Each array contained 
4900 microrafts (70 × 70 array). Each microwell array was coated with a solution of 
poly(styrene-co-acrylic acid) (PS-AA) in GBL co-mixed with γFe2O3 nanoparticles and 
degassed under vacuum to remove air bubbles.18 The array was submerged in a jar of the same 
solution and pulled out by a stepper motor at a rate of 1 mm/s. This procedure of dip-coating 
resulted in a droplet of solution deposited within each microraft. The array was baked at 95°C 
for 12 h period producing a hard, concave magnetic element, or microraft. Each array contained 
4900 microrafts (70 × 70 array). The microraft array was subsequently adhered to a polystyrene 
cassette using PDMS. 
4.2.3 Microscopy setup 
An MVX10 MacroView upright microscope (Olympus, Center Valley, PA) equipped 
with an ORCA-Flash 4.0 CMOS camera (Hamamatsu, Bridgewater, NJ) was used to acquire 
bright field and fluorescence micrographs. The MVX10 MacroView was fitted with a 
PS3H122 Motorized Focus Drive and a H138A motorized XY translational stage manipulated 
by a ProScan H31 Controller and a PJ2J100 joystick (Prior Scientific Inc., Rockland, MA). A 
Lambda 10-3 optical filter changer was utilized to control an emission filter wheel (LB10-
NWE), an excitation filter wheel with SmartShutter (LB10-NWIQ) and a stand-alone 
SmartShutter shutter (IQ25-SA) (Sutter Instrument, Novato, CA). A sedat filter set (89000 – 
ET – Sedat Quad; Chroma Technology Corp, Bellows Falls, VT) containing 5 excitation filters 
(350 ± 50 nm, 402 ± 15 nm, 490 ± 20 nm, 555 ± 25 nm, 645 ± 30 nm), 4 emission filters (455 
± 50 nm, 525 ± 36 nm, 605 ± 52 nm, 705 ± 72 nm) and a multiband dichroic enabled 
measurement of fluorescence in the blue, green, red and far red wavelengths. A lumen 200 arc 
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lamp (Prior Scientific Inc., Rockland, MA) provided light for fluorescence excitation. All 
microscopy equipment was controlled by custom software written in MATLAB (MathWorks, 
Natick, MA) and using a Micro-Manager (Open Imaging, San Francisco, CA) core.20, 21 A 
custom-made incubator was made to fit around the microscopy set-up to regulate temperature, 
humidity and CO2 concentration during time-lapse microscopy experiments. 
4.2.4 Preparation of microraft arrays for the cytotoxicity assays 
Prior to experiments on the microraft array, the array was treated for 5 min in a plasma 
cleaner (Harrick Plasma, Ithaca, NY). The array was then washed with 100% ethanol and 
subsequently washed ×5 with PBS. The microraft array was coated in 0.1 wt% bovine gelatin 
in PBS and incubated at 37°C for ≥2 h. The gelatin solution was aspirated and the array was 
washed ×3 with PBS before plating cells. 
4.2.5 Generation of dendritic cells (DCs) from CD34+ progenitors 
Dendritic cells were differentiated from CD34+ cells using a modification of a 
previously described method.22 De-identified cryopreserved leukapheresis products from 
healthy donors treated with G-CSF to mobilize CD34+ cells were obtained from the 
Hematopoietic Progenitor Cell Laboratory at UNC Hospitals. On Day 1, a cryopreserved 
leukapheresis product was thawed, peripheral blood mononuclear cells (PBMCs) were isolated 
by Ficoll-Paque PLUS density gradient centrifugation, and the CD34 Microbead Kit UltraPure 
was used to isolate CD34+ cells. CD34+ cells were plated at 3 mL/well in 6 well ultra-low 
attachment plates at a concentration of 3 × 105/mL in CTS AIM V media with 10% human AB 
serum (complete media, CM), supplemented with 800 U/mL GM-CSF, 100 ng/mL Flt3-ligand 
and 50 ng/mL SCF.  Cells were incubated for 72 hours in a 5% CO2 incubator at 37oC. Once 
differentiation was initiated, immature DCs were handled with polypropylene transfer pipets 
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(as polystyrene serological pipets could induce early maturation of the DCs). Cells were 
maintained at a concentration of < 0.8 × 106/mL. On days 4 and 6, cells were counted, 500 μL 
of CM was added to each well to maintain a 3 mL volume, and fresh cytokines were added to 
final concentrations of 800 U/mL GM-CSF, 100 ng/mL Flt3-ligand, 50 ng/mL SCF and 500 
U/mL IL-4. On days 8 and 10, cells were counted and split to maintain a concentration < 0.8 
× 106/mL and 800 U/mL GM-CSF, and 500 U/mL IL-4 was added to each well. Immature DCs 
were cryopreserved on Day 12 in FBS with 10% DMSO.   
 After thawing, immature DCs were expanded in CM, GM-CSF and IL-4. Final 
differentiation of immature DCs into mature DCs was initiated 4 days prior to peptide-pulsing 
by plating the immature DCs at a concentration of 1.25 – 1.5 × 106/mL in fresh CM with GM-
CSF, IL-4 and 20 ng/mL TNF-α. The following day, 20 ng/mL TNF-α was added to the media. 
Forty-eight hours prior to peptide pulsing the cells, GM-CSF, IL-4 and TNF-α were 
replenished, and 1000 U/mL IFN-α and 1000 U/mL IL-6 were added to the cultures. TNF-α 
was added 24 hours later, and the cells were peptide-pulsed the following day.  
Matured DCs were pelleted and resuspended at a concentration of 1 × 106 live cells/mL 
in CM supplemented with GM-CSF, IL-4 and TNF-α. Peptides (M1p or PR1) were co-
incubated with DCs at a concentration of 2 μg/mL of peptide and incubated for at least 18 
hours. DCs were washed once with CM to remove excess peptide prior to use for T cell 
stimulation or in bulk cytotoxicity assays. 
4.2.6 Generation of cytotoxic T lymphocytes (CTLs) 
PBMCs were isolated from another CD34+ leukapheresis product from the same donor 
using Ficoll-Paque PLUS. PBMCs were suspended at a concentration of 10 × 106/mL in CM 
and plated in two T175 culture flasks (5 × 108 cells/flask). Monocytes were allowed to adhere 
 106  
to the flasks for 2 hours, and non-adherent cells (NADs) were collected. CD8+ cells were 
isolated from 5 × 108 NADs by magnetic separation using the CD8+ T cell isolation kit 
(Miltenyi Biotec).   
 The cytotoxic T lymphocyte (CTL) culture was initiated by incubating 1 × 107 CD8+ T 
cells with 5 × 105 M1p pulsed DCs (20:1 CTL:DC ratio) in 10 mL CM supplemented with 30 
ng/mL IL-21. Cultures were incubated for 3 days without disturbing the co-incubated cells, 
after which the cells were fed with CM supplemented with 10 ng/mL IL-7 and 10 ng/mL IL-
15 every two days, keeping the concentration of live cells at 1 × 106/mL. Conditioned media 
(media already in the culture) was kept as 1/3 of the final culture volume each time the cells 
were fed. CTLs were restimulated with DCs pulsed with 2 μg/mL M1p at a 50:1 CTL:DC ratio 
11 days after initiation of the culture in media supplemented with IL-21, IL-7 and IL-15. After 
3 days, cells were plated at a concentration of 1.25 × 106/mL and fed every 2 to 3 days with 
CM supplemented with IL-7 and IL-15. One hundred U/mL IL-2 was added 19 days after 
initiation of the culture.23 CTLs were restimulated 21 and 34 days after culture initiation, and 
the CTLs were cryopreserved in aliquots 41 days after initiation of the culture. 
4.2.7 Tetramer analysis 
For tetramer staining, 1 × 106 cells (bulk culture) or 1 × 105 cells (CTL clones) were 
washed with DPBS + 0.5% BSA and resuspended in 100 μL DPBS + 0.5% BSA. Ten μL of 
APC-labeled M1p/HLA-A*02:01 tetramer or negative tetramer was added to each sample. PE-
Cy7-anti-CD8 antibody and a FITC labeled lineage mix of CD4, CD14, CD16 and CD19 
antibodies were added, and the samples were incubated at 4oC for 30 minutes. The cells were 
washed and resuspended in DPBS + 0.5% BSA + 1 μg/mL DAPI. Sample acquisition was 
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performed on a FACSCanto flow cytometer (BD Biosciences) and data was analyzed using 
FlowJo version 7.6.5 (FlowJo LLC, Ashland, OR). 
4.2.8 Bulk culture cytotoxicity assay 
CTLs were restimulated with M1p pulsed DCs at a CTL:DC ratio of 50:1 four days 
prior to the cytotoxicity assay, left undisturbed for 3 days, and plated the day before the assay 
at a concentration of 1 × 106/mL in CM supplemented with IL-2, IL-7 and IL-15. The day prior 
to the cytotoxicity assay, differentiated DCs were stained with 0.6 μM DDAO-SE in DPBS for 
15 minutes at 37oC, followed by incubation in CM for 30 minutes, pelleted and resuspended 
in CM supplemented with GM-CSF, IL-4 and TNF-α. DCs were plated at a concentration of 1 
× 106/mL in a 24 well low binding plate, and M1p or PR1 peptide was added at a concentration 
of 2 μg/mL.   
 For the cytotoxicity assay, DCs were washed and resuspended in CM at a concentration 
of 0.5 × 106/mL. One hundred μL (50,000 DC target cells) was added to each assay well in a 
96 well round bottom plate. CTLs were incubated for 30 minutes in serum-free AIM V media 
with 1 μM Cell Tracker Green CMFDA dye, pelleted, and incubated in CM for 30 minutes. 
CTLs were pelleted and resuspended in CM at a concentration of 1 × 106/mL. To initiate the 
cytotoxicity assay, CTLs were added to the 96 well plate with DCs at either a 1:1 ratio (50,000 
CTLs/well) or a 2:1 ratio (100,000 CTLs/well). The final assay volume was 200 μL. Target 
cells were incubated without CTLs as a control. After a 6 hour incubation, cells were pelleted 
in the 96 well plate, washed once with DPBS, and resuspended in 200 μL DPBS with 1 μL 
LIVE/DEAD Fixable Violet Dead Cell Stain per 1 mL DPBS. Cells were incubated for 30 
minutes at room temperature, washed with DPBS and fixed in 2% formaldehyde. Cells were 
 108  
analyzed on a Miltenyi MACSQuant flow cytometer (Miltenyi Biotec) with data analysis using 
FlowJo version 7.6.5. 
4.2.9 Restimulation of CTLs and isolation of CD8+ cells prior to plating on the microraft 
arrays 
Cryopreserved CTLs were thawed and restimulated with M1p pulsed DCs at a CTL:DC 
ratio of 50:1. After 3 days, CD8+ T cells were isolated using the CD8+ T cell isolation kit and 
plated at a concentration of 1 × 106 cells/mL in CM supplemented with IL-7, IL-15 and IL-2. 
CD8+ T cells were plated on microraft arrays 2 to 3 days later. 
4.2.10 Single T cell cytotoxicity assay 
Autologous DCs were pulsed with either M1p or PR1 16-18 h prior to the cytotoxicity 
assay. Both sets of DCs were stained with 1 mg/mL Hoechst 33342 and 50 nM Sytox Green 
following the manufacturers’ protocols prior to plating. Cells were deposited on microraft 
arrays in phenol-red free RPMI 1640 supplemented with 10% human AB serum, 100 U/mL 
penicillin, 100 µg/mL streptomycin and 20 mM HEPES. For each cytotoxicity assay, two 
microraft arrays were prepared, and M1p pulsed DCs were added to one array while PR1 
pulsed DCs were added to the second array at cell:microraft ratios of 30:1. Both arrays were 
centrifuged at 400 × g for 4 min and the media was aspirated. CD8+ T cells from the M1p 
culture were stained with 500 nM CellTracker Deep Red and 50 nM Sytox Green following 
manufacturer’s protocols and were added to both arrays at a cell:microraft ratio of 1:1. The 
arrays were again centrifuged at 400 × g for 4 min and the media was aspirated. Culture media 
containing 50 nM Sytox Green was placed over each array and the array covered with a cover 
slip (50 mm diameter). Arrays were then placed on the microscopy stage and imaged every 30 
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min for 6 h. During microraft array imaging, an incubator housing the microscope was 
maintained at 37°C, 60% relative humidity and 5% CO2. 
4.2.11 Image acquisition 
A customized MATLAB program controlled the microscope to acquire bright field and 
fluorescence images of the microraft array at designated time points. A graphical user interface 
(GUI) was designed to permit input of user-selected parameters such as fluorescence channel 
selection, camera exposure, microraft array geometry, microraft array numbers and time-lapse 
conditions.24 A 5% overlap between imaged fields of view was used in all experiments. 
4.2.12 Image processing and analysis 
In parallel with the image acquisition, the MATLAB program processed and analyzed 
the acquired images. The bright field images were used to identify individual microraft 
locations. Flat-field correction was performed on each bright field image to correct for uneven 
illumination intensity.25 Otsu’s method was then used to calculate a threshold for each image, 
and the image was converted to binary.26 Due to the optical properties of microrafts, the borders 
of each microraft appear dark in bright field micrographs enabling facile identification of 
individual microraft borders. The binary images were further processed to fill the interior of 
each microraft border and remove any resulting objects that were larger than 1.5× or smaller 
than 0.5× the microraft size eliminating debris. The positions of all microraft were identified 
just before each time point. 
 Fluorescence images were processed in a similar fashion. A top hat filter was applied 
with a disk structuring element having a radius twice the nominal diameter of a cell to remove 
background fluorescence.27, 28 Otsu’s method was utilized to determine a threshold for each 
image and the threshold was applied to convert each image to binary.26 The pixel locations and 
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intensity values of each fluorescence image were determined for each individual microraft. 
Additionally, a watershed algorithm was applied to each image in the far red channel 
(corresponding to cells stained with CellTracker Deep Red) to count the number of individual 
cells on each microraft.29-31 
4.2.13 Selection of cells for release 
The locations of individual microrafts were determined using the image processing and 
analysis software described above. Microrafts containing a single CD8+ cell were identified 
from the watershed algorithm using CellTracker Deep Red fluorescence as a marker of CD8+ 
cells. These microrafts were sorted based on the increase in Sytox Green fluorescence intensity. 
Automatically identified microrafts were re-screened after gelatin encapsulation (see below) 
to ensure that a single CellTracker Deep Red-positive cell (CD8+ cell) remained on the 
microraft. 
4.2.14 Microraft/cell release transfer to a 96-well plate 
Upon completion of the cytotoxicity assay, the arrays were overlaid with a thin layer 
of gelatin as described previously.17 The gelatin flowed into the cup-shaped microrafts to 
encapsulate the non-adherent cells ensuring that the cells remained on their microrafts during 
microraft release and retrieval. Briefly, the culture media above the array was replaced with a 
thin layer of 5 wt% bovine gelatin in PBS and the array was centrifuged at 400 × g for 4 min. 
The array was then incubated for 10 min at 37°C. The array was washed and then incubated at 
4°C for 5 min to solidify the gelatin within the microrafts and cold (4°C) culture media was 
overlaid onto the arrays. For these experiments, the incubator surrounding the microscope was 
cooled to 24°C just prior to gelatin overlay of the array. 
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 Microraft isolation was then carried out by actuating a small needle (10 µm tip, 100 
µm base, 5 mm long) to puncture the PDMS of the microraft array and eject individual 
microrafts as described previously.17-19 Released rafts were then captured by a magnetic wand 
mounted on a computer controlled 3-axis motor and deposited into a 96-microwell plate as 
described previously.17 
4.2.15 Preparation of feeder cells for T cell expansion 
PBMCs were isolated from 3 different buffy coats using Ficoll-Paque PLUS or 
Lymphoprep, diluted to 2 × 106/mL in cold DPBS, and irradiated at 35 Gy in an RS 2000 
Biological Irradiator (Rad Source Technologies, Inc., Suwanee, GA). After irradiation, equal 
numbers of PBMCs from each buffy coat were combined to a concentration of 1 × 106/mL in 
CM supplemented with 20 ng/mL IL-7, 20 ng/mL IL-15 and 200 U/mL IL-2. One hundred μL 
was added per well to two 96 well round bottom plates; the volume was brought up to 200 μL 
by the addition of 100 μL of CM per well to the plate used for collecting cells released from 
the microraft array. The second plate was used for the parallel limiting dilution assay. 
4.2.16 Limiting dilution 
CD8+ CTLs, prepared as described for the microraft array cytotoxicity assays, were 
serially diluted 10-fold in CM from a concentration of 500,000 cells/mL to 5 cells/mL. One 
hundred μL of the 5 cells/mL dilution was added to each well of a 96 well plate containing 
irradiated feeder cells, for an expected concentration of 0.5 CTLs/well. 
4.2.17 T cell expansion 
Microrafts containing selected CTLs were isolated as described above in to 96-well 
plates containing feeder cells. Cells released from the microrafts and cells plated by limiting 
dilution were expanded in parallel using minor modifications of the protocol described by 
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Perna el al.32 OKT3 antibody was added to a final concentration of 50 ng/mL 2 to 3 days after 
plating the cells. Cells were fed weekly by adding 20 μL of CM supplemented with a 10× 
concentration of cytokines and OKT3 antibody. Expanding single cell clones were transferred 
from the 96 well plates between days 11 and 19 after plating. Clones were transferred to 1 mL 
of CM supplemented with IL-2, IL-7 and IL-15 in a 24 well plate, and tetramer staining was 
performed 2 days later. Tetramer positive clones were expanded with a mix of irradiated 
PBMCs and an EBV-immortalized lymphoblastoid cell line (EBV-LCL) as feeder cells.32 
Cryopreserved PBMCs from the 3 buffy coats used for the feeder plates were thawed and 
resuspended in cold DPBS at a concentration of 2 × 106/mL. EBV-LCLs (generated by 
immortalizing human B cells with Epstein Barr Virus (EBV) at the UNC Lineberger Tissue 
Culture Facility) were resuspended in cold DPBS at a concentration of 1 × 106/mL. PBMCs 
and EBV-LCLs were irradiated at 35 Gy and resuspended in CM supplemented with IL-2, IL-
7, IL-15, and OKT3 antibody. 2 × 106 PBMCs and 0.15 × 106 EBV-LCLs in 2 mL of media 
were added per well to 3 wells of a 12 well plate, and the expanding CTL clones were pelleted 
and added to the wells.  CTLs were fed 4 days later by pelleting and resuspending in 2 mL CM 
supplemented with IL-2, IL-7 and IL-15. Three days later, CD8+ cells were isolated using 
Miltenyi’s CD8+ T cell isolation kit, and cell pellets were frozen at -80oC for TCR α and β 
chain CDR3 sequencing. 
4.2.18 Analysis of TCR α- and β-chain CDR3 sequencing 
RNA was isolated from approximately 22,500, 150,000 and 60,000 cells from the B8, 
D10 and F9 CD8+ T cell clones, respectively, using Qiagen’s RNeasy Micro Kit and stored in 
aliquots at -80oC. Analysis of TCR α- and β-chain rearrangements was performed using 
multiplex RT-PCR as described by Kim et al.33, which is a modification of the method 
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described by Seitz et al.34 Briefly, an aliquot of RNA was thawed, and the initial RT-PCR 
reaction was performed using the OneStep RT-PCR kit.33 TCR β-chains were amplified from 
1 μL of the RT-PCR product in a run-off reaction, followed by semi-nested PCR using the Fast 
Start High Fidelity PCR System. Reactions that produced PCR products visible by agarose gel 
electrophoresis were purified using the Qiagen PCR Purification Kit and sequenced using the 
UP primer described by Kim et al.33 TCR α-chains were amplified by nested touchdown PCR 
using 1 μL of the RT-PCR reaction as previously described33, using the Fast Start High Fidelity 
PCR System. PCR products were analyzed by agarose gel electrophoresis, purified using the 
Qiagen PCR Purification Kit, and sequenced using the Cα-in primer.33 Sequencing was 
performed at the UNC Genome Analysis Facility (University of North Carolina, Chapel Hill, 
NC), and sequences were analyzed to determine the V and J alleles as well as the CDR3 
sequence using IMGT/V-Quest (http://www.imgt.org/IMGT_vquest/vquest).35, 36 One clone 
(F9) did not produce readable sequences using the protocol described above, possibly due to 
poor quality RNA. The TCRβ-chain rearrangement of this clone was analyzed using a 
modification of another multiplexed RT-PCR protocol for single cell TCRβ analysis.37  Briefly, 
an aliquot of RNA was thawed, and multiplex RT-PCR was performed in a 50 μL reaction 
using the SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity DNA 
Polymerase, 10 U RNase Inhibitor, and 2.8 μL of a mix of 26 primers (external primer set (28); 
final concentration of 0.21 μM per primer). PCR products were purified using the Qiagen PCR 
purification kit, analyzed by agarose gel electrophoresis and sequenced using the internal hCbi 
primer.37  Sequencing and sequence analysis were performed as described above. 
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4.2.19 Statistics 
Cytotoxicity results on the microraft array were compared using the nonparametric 
Mann-Whitney U-test. All statistics were performed in MATLAB. 
4.3 Results and Discussion 
4.3.1 Microraft arrays for selection of non-adherent cells 
Microraft arrays are comprised of a regular pattern (70 × 70) of transparent 
microcarriers or microrafts on which cells are cultured and assayed over time by microscopy 
(Figure 4.1A, B). The microrafts fabricated from a magnetic polystyrene possess a concave 
surface of 120 μm depth enhancing retention of cells on their surfaces during assay setup and 
performance. After identification of cells of interest based upon a fluorescent read-out over 
time, five percent gelatin in PBS is poured on the array and gelled encapsulating the cells 
within the concave surface of their microraft. To release a selected microraft with cells from 
the array, a microneedle situated under the microscope stage pushes through the PDMS 
membrane underlying the microraft and releases the selected microraft from the array (Figure 
4.1C, D). The microraft with gel-encapsulated cell(s) is then readily captured by an overlaying 
magnetic wand dipped into the media above the array (Figure 4.1E). The wand with captured 
microraft is then placed into the well of a 96-well plate. The microraft is released by the 
dissipation of surface tension forces created by the residual fluid droplet on the wand tip and 
by repulsion of the wand magnet by a block magnet underlying the 96-well plate.  The 
microraft is then pulled down to the bottom of the well by the block magnet (Figure 4.1F). 
Microrafts can be visualized by bright field microscopy, and the release of microrafts can also 
be confirmed by their presence in the 96-well plate and absence on the array (Figure 4.1G, H). 
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4.3.2 Design of T cell mediated cytotoxicity assay 
While the microraft array format can be employed for multiple types of experiments 
and cells, this series of experiments developed an assay for the selection and capture of T cells 
based upon their cytotoxicity. The microraft arrays were seeded with autologous DCs (“target” 
cells) that had been pulsed with either M1p or PR1 peptides and labeled with Hoechst dye. 
Targets were applied to the array at a ratio of 30 cells per microraft (147,000 cells per array). 
CD8+ T cells were labeled with CellTracker Deep Red and placed onto the array at a 
cell:microraft ratio of 1:1 in order to maximize the number of microrafts that contained a single 
T cell. Cells settled onto the array in a stochastic manner so that the number in each well across 
the array followed the Poisson distribution.19, 38 By the Poisson distribution, roughly 1/3 of the 
wells (36.8% or 1803 wells) are predicted to possess a single CD8+ T cell, 26.4% (1205) are 
predicted to contain >1 T cell and 36.8% (1803) are expected to have 0 T cells. The media 
overlaying the array contained Sytox Green, a DNA binding dye that is membrane 
impermeable. The assay was intended to identify microrafts that contained a single T cell and 
showed a high rate of cytotoxicity as evidenced by increasing green fluorescence over a 6 hour 
time course (Figure 4.2A-C). Because both the target cells and T cells were applied to the 
media over the microraft array, individual microrafts had different numbers and ratios of target 
and T cells. (Figure 4.2D, E). Fluorescence images were obtained every 30 min for 6 hours 
and the development of green fluorescence over time was measured for each microraft. (Figure 
4.2F, G). 
4.3.3 M1p specific T cell culture 
To evaluate the microraft cytotoxicity assay, a T cell culture was generated against the 
influenza M1p antigen. M1p/HLA-A*02:01 tetramer enumeration showed that 48.4% of CD8+ 
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T cells were specific for M1p (Figure 4.3A). The bulk culture displayed antigen specific 
cytotoxicity against M1p pulsed autologous DCs compared to autologous DCs pulsed with the 
leukemia associated antigen PR1 (Figure 4.3B).39 
4.3.4 Overall analysis of cytotoxicity on microraft arrays 
All analyses performed on the microraft arrays compared development of green 
fluorescence over time in microrafts that contained either 0 or 1 CD8+ T cell. Microrafts with 
0 T cells were considered the control and reflected the rate of spontaneous target cell death 
over the time of the investigation. A total magnification of 4× was used for scanning microrafts, 
resulting in a pixel size of 1.62 μm/pixel. This magnification was chosen because it allowed 
for easy identification of single cells while maintaining a large field of view to minimize image 
acquisition time. Each 70 × 70 microraft array required 49 images per channel at this 
magnification with a 5% overlap of images. Image acquisition of a single array using bright 
field (100 ms camera exposure) plus 3 fluorescence channels (200 ms camera exposure each) 
required 216 ± 4 s to complete (n = 10). An autofocus algorithm was used to maintain focus 
for each image and required 99 ± 2 s to complete and was accurate to within a single depth of 
field with 100±0% efficiency (n = 50). The resulting total microraft array scan time (autofocus 
and image acquisition) was 315 ± 5 s.  
In parallel with the image acquisition, the MATLAB program processed and analyzed 
the acquired images. The MATLAB GUI was used to select the desired combination of bright 
field and fluorescence channels for imaging. The processing time of each set of images was 
faster than the microscope stage movement and image acquisition, so no additional time was 
added to the total scan time. The bright field images were used to identify individual microraft 
locations. Due to the elastomeric nature of PDMS, image analysis was needed to accurately 
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locate the exact positions of microrafts on the array. The microraft segmentation method 
consisted of background estimation, flat field correction, thresholding and morphological 
filtering. The vast majority of microrafts (99.8±0.8%) were correctly identified without false 
positives (n = 100 images, 100-121 microrafts per image). The microrafts that were not 
correctly identified were missed due to debris obscuring the microraft. 
 The fluorescence images were analyzed to determine the intensity, area, position and 
number of cells displaying each fluorophore (Hoechst, Sytox Green and CellTracker Deep 
Red). Flat-field correction, top hat filtering and Otsu’s thresholding was applied to each image 
to produce a binary mask of the cells on the microraft array.  Within the mask created by each 
fluorophore, the intensity, location and number of pixels was recorded for each microraft. The 
number of T cells on each microraft was counted from the far-red fluorescence after 
implementation of the watershed algorithm. This method generated 0.04 ± 0.26 false positives 
and 0.07 ± 0.28 false negatives per microraft compared to manual counting of the number of 
far-red-positive cells on each microraft. False negatives were often due to two or more cells in 
very close proximity that were not successfully separated by the algorithm or due to cells with 
very low-intensity far-red fluorescence. False positives were due to light from a very bright 
cell refracted off the edge of the microraft. The watershed segmentation method ultimately 
resulted in a sensitivity of 96±16% in identifying cells with CellTracker Deep Red fluorescence 
and a false cell identification rate of 1.5±9.0% (n = 401 microrafts). The watershed 
segmentation was most accurate when low numbers of cells were located on a microraft. For 
this reason, the data obtained from the watershed segmentation was only used to count T cells. 
 Cytotoxicity or cell killing was measured by summing the Sytox Green pixel intensity 
within the Hoechst fluorescence area on each microraft. Using the Hoechst positive regions on 
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each microraft as a mask for the Sytox Green fluorescence greatly reduced spurious 
measurements due to debris and disintegrating cells and their fragments. The effector cell count 
and cytotoxicity information was recorded for each microraft at each time point to generate 
temporal traces of cytotoxicity corresponding to specific numbers of effector cells present. 
Microrafts containing a single effector cell were sorted in descending order based on 
cytotoxicity over the entire 6 h imaging period. The microrafts with the greatest cytotoxicity 
were selected for isolation. 
Figure 4.4 shows the results of 2 microraft arrays analyzed in parallel. The first array 
(Figure 4.4A-H) contained M1p-pulsed DCs as targets and the second array (Figure 4.4I-P) 
contained PR1-pulsed DCs. Because the assay was intended to identify individual highly 
cytotoxic T cells, the arrays were first analyzed to identify microrafts with 0, 1 or >1 CD8+ T 
cell (Figure 4.4A, I), and the increase in green fluorescence at each microraft was measured 
(Figure 4.4B, J). These general analyses showed that the T cells distributed evenly over the 
array, and there did not appear to be any particular regions on the arrays with abnormally strong 
increases or decreases in green fluorescence. Several different methods were considered to 
analyze the inter-microraft cytotoxicity. In the initial analysis, the microrafts were segregated 
into those with 0 T cells and those with 1 T cell (microrafts with >1 T cell were excluded). The 
difference in green fluorescence at t = 6h and t = 0h was measured for each microraft. The 
differences in fluorescence across the arrays are shown (Figure 4.4C, D, K, L). This 
representation proved to be difficult to visualize and interpret. However, when the fluorescence 
differences observed in the 0 T cell microrafts were compared to the differences observed in 
the 1 T cell microraft, there was a small, but statistically significant, difference observed in the 
M1p array but not the PR1 array (Figure 4.4E, M). Since the assay monitors cellular processes 
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over time, more information on a per T cell basis is available than the simple differences over 
2 time points. The change in green fluorescence over time for each microraft was measured for 
microrafts with 0 T cells (Figure 4.4F, N) and 1 T cell (Figure 4.4G, O), and again there was 
significant overlap in the rate of fluorescence change over time. While many microrafts 
exhibited similar rates of increase in green fluorescence, there were some microrafts that 
exhibited high rates of apparent cytotoxicity. To identify these microrafts, the median rate of 
green fluorescence ± 4 median absolute deviations for the 0 T cell microrafts in each array was 
calculated. The rate of green fluorescence increase for all microrafts with 1 T cell was obtained, 
and only microrafts with green fluorescence > 4 median absolute deviations from the median 
at all time points were selected as “best killers”. A total of 55 microrafts met this criterion in 
the M1p array and 8 met the criterion on the PR1 array (Figure 4.4H, P). 
4.3.5 Isolation and expansion of T cells based upon cytotoxicity 
Individual CD8+ T cell expansion was performed on the original T cell culture (Figure 
4.3) by limiting dilution. Cells were diluted to an expected density of 1 cell per 2 wells into a 
96-well plate and incubated for 3 weeks. The 96 most active T cells from the M1p array were 
sorted using the microraft release device into a 96-well plate and again allowed to clonally 
expand for 3 weeks. The limiting dilution and microraft release experiments were performed 
twice. Of the 192 microraft release procedures, 122 resulted in the single selected microraft 
being deposited into a well. From the two 96-well plates that received cells by limiting dilution, 
4 wells demonstrated T cell expansion; however, none of these clones demonstrated specificity 
for M1p by tetramer analysis (data not shown). Of the 122 wells with single microrafts, 3 clonal 
populations were expanded. All 3 of these CD8+ T cell populations demonstrated high avidity 
binding to M1p/tetramer (Figure 4.5A-L). RNA was extracted from small aliquots of these 
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populations, and the CDR3 regions of the TCRα and TCRβ chains were amplified for 
sequencing using a multiplex RT-PCR protocol modified from single-cell TCR sequencing 
methods. The CDR3 for TCRβ chains was determined for all 3 clonal populations, and the 
TCRα CDR3 sequence was determined for 2 of the clones (Table 4.1). 
4.4 Conclusions 
The purpose of this series of experiments was to develop microraft-based visualization 
and capture methods for the evaluation of immune responses. Most evaluations of immune 
responses are performed as experiments on bulk populations; however, both effector immune 
cells and potential immune targets exist as heterogeneous populations in vivo. Identifying 
individual cells with particular properties could provide better insight into the characteristics 
of effector or target cells that either support or impair a robust immune response in infectious 
or autoimmune disease or cancer. 
 Our group and others have developed microraft arrays for the functional analysis of 
rare cells40, 41; however, this project sought to develop several technological advances to make 
a device that could analyze the interactions and changes in multiple cell populations 
simultaneously over time and viably sort cells of interest for further characterization. Because 
one of the most important functional characteristics of CD8+ T cells is antigen specific 
cytotoxicity, we adapted the microraft array platform to interrogate single-cell cytotoxicity 
with subsequent cell sorting. To develop this assay, methods to analyze 2 cell types and 3 
fluorescence channels were implemented, with the resulting platform being able to measure 
the cytotoxic ability of >1,000 individual T cells against target cells. Because we wished to 
have high-efficiency cell sorting capability as part of the assay, we used the previously 
developed microraft release device and were able to isolate 1 CD8+ T cell every 35 s based 
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upon the cytotoxicity measurements. This method of single cell isolation is roughly 3× faster 
than micromanipulation, which has been used on microwell platforms previously, and it 
minimizes the risk of cross contamination by not repetitively using microcapillaries for cell 
transfer.41, 42 While fluorescence activated cell sorting (FACS) rapidly sorts non-adherent cells, 
it is limited in its ability to sort based upon a true functional readout. In addition, the 
temperatures, pressures, and other stressors applied to cells during FACS and the TCR 
activation of T-cells via the peptide/MHC multimers can reduce cell viability for downstream 
applications.15, 16 
 To test our assay and cell-sorting capabilities, we produced a T cell culture against the 
well-defined M1p influenza antigen. This antigen elicits robust T cell responses in subjects 
expressing HLA-A*02:01, and a tetramer reagent is readily available. The anti-M1p culture 
contained a high percentage of antigen-specific T cells, as evidenced by tetramer enumeration. 
During the design and optimization of the microscope and microraft release device, the T cell 
culture and the autologous DCs that were used as stimulators and also target cells on the 
microraft array were cryopreserved, which likely affected the long-term viability of both the 
DCs and T cells and the ability of the T cells to clonally expand. Although the T cells retained 
significant specific cytotoxicity following thawing (Figure 4.3B), the culture did not expand 
as it had prior to cryopreservation. 
 Single cell killing analyses provides a different evaluation of T cell mediated killing 
compared to conventional bulk cytotoxicity assays. Bulk cytotoxicity assays are typically 
performed with an excess of T cells (effector, E) to target (T) cells. In our assay, the culture 
was so active that specific cytotoxicity was easily detectable at an E:T ratio of 1:1; however, 
it is common for specific cytotoxicity to be detectable only at an E:T ratio of > 10:1. In our 
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single cell assay, each microraft had 1 CD8+ T cell and an average of 30 target cells, providing 
a per microraft E:T ratio of 1:30. In a bulk cytotoxicity assay, an excess of T cells admixed 
with a large pool of target cells (E>T) would allow even a rare population of highly active 
CD8+ T cells to interact and kill an almost limitless number of target cells. This is the opposite 
situation in the microraft array, where there is no enrichment in the number of highly active 
CD8+ T cells (E<T), and the absolute maximum killing achievable by any 1 T cell is only the 
number of targets (< 0.1% of the total) in the 1 microraft. While statistical differences in Sytox 
Green fluorescence were seen between microrafts containing CD8+ T cells and microrafts 
containing only targets, the statistical significance is more a function of the large numbers of 
microrafts analyzed and not the magnitude of the difference in fluorescence (Figure 4E, 4M). 
It is quite possible that T cell cultures that contain a smaller proportion of highly active antigen-
specific CD8+ T cells will not show any increase in overall cytotoxicity using the microraft 
arrays, but the few highly active, antigen-specific T cells will individually demonstrate high 
rates of killing. 
 This experiment was designed to identify the “best killer” from a T cell culture so 
selection was determined based upon a single T cell being able to kill multiple targets. As such 
the number of targets per well was set high with a mean number per microraft of 30. Because 
the target cells used in these experiments were ~90% viable, the median number of dead cells 
per well was 3, regardless of the presence of a T cell or not. These dead target cells likely 
increased the distribution of Sytox Green fluorescence in microrafts that did not contain a T 
cell, and consequently, diminished the observed difference between T cell mediated and T cell 
independent cytotoxicity. In our experience, DC cultures that have not been maintained for 
prolonged periods of time have higher viability, which would improve the discrimination 
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between T cell dependent and independent killing. Reducing the mean number of target cells 
per microraft in this type of experiment to <10 target cells per microraft would have greatly 
reduced the T cell independent death rate, and likely would have still provided sufficient targets 
to identify the “best killers” in this application. 
While the microraft array was designed in this experiment to identify CD8+ T cells that 
exhibit the highest rate of cytotoxicity, the array and experiments can be modified for other 
purposes. While this initial experiment identified the “best killer” T cells, by adjusting the E:T 
ratio to 1:1 per microraft, the array can be used to assess the overall antigen-specific 
cytotoxicity of a T cell culture with an output similar to that of a traditional ELISPOT 
experiment.8 However, in addition to enumerating antigen-specific T cells based on 
cytotoxicity (as opposed to cytokine secretion by ELISPOT), the detected T cells can be 
recovered and clonally expanded if desired. Since each cell in the microraft contains a single 
TCR, this methodology allows for the sequencing of high avidity functional TCRs, which 
could be used for T cell engineering applications to target intracellular antigens presented by 
MHC.   
In addition to measuring T cell function, the microraft array design could also be used 
to measure the heterogeneity of responses in target cells, such as primary tumor cells, to a 
homogeneous population of T cells. In this format, microrafts containing a T cell that show 
little to no target cell death could be selected and the target tumor cells further characterized 
or expanded in vitro to determine the mechanism of immune resistance. Finally, the array 
system can be engineered to monitor the interactions of more than 2 populations. The current 
microscope configuration allows 4 fluorescence markers to be used easily. The fourth marker 
could be used to label a third cell population, e.g. regulatory CD4+ T cells (Treg), or 
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mesenchymal stem cells (MSC), to measure, across multiple cellular ratios, the influence of 
different cell populations on immune cell function. 
 The T cell isolation procedure using the microraft arrays requires encapsulating the 
entire array in gelatin and performing needle release on individual microrafts. We have used 
this approach before on highly proliferative non-adherent cell lines17; however, we wanted to 
see if this approach could yield clonally expanding T cell populations. In parallel experiments 
where we sorted microrafts and performed limiting dilution single cell transfer from the same 
culture into two 96-well plates, we were able to clonally expand 3 T cells from microraft 
sorting and 4 using limiting dilution. While the expansion efficiency was not high, we suspect 
this is a reflection of the time that the T cells were cryopreserved (8 months) prior to use in 
these experiments. The fact that a similar number of clones were expanded using both 
strategies suggests that the microraft release method does not dramatically worsen T cell 
viability. The expanded T cell clones from the microrafts were antigen specific, and we were 
able to sequence the paired TCRα and TCRβ CD3 region from 2 of the 3 clones. Other paired 
TCRα and TCRβ strategies have been developed that could be used in this application.43 
 In conclusion, we have developed a microraft array that allows for the measurement of 
individual T cell cytotoxicity as well as the isolation of selected T cells for clonal expansion 
and further analysis. This array can be broadly applied for other uses in measuring immune 
cell function. Additionally, the microraft array geometry is easily scalable and the microraft 
size and distance between microrafts can be decreased. Microraft arrays having individual 
microrafts measuring 50 μm × 50 μm with a 20 μm gap have been fabricated on a 2.5 cm × 
2.5 cm array yielding >125,000 microrafts on a single array. The total array size can also be 
scaled or array cassettes can be designed to hold multiple arrays to even further increase the 
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number of elements. This large number of elements will be essential for the identification of 
rare antigen-specific CTLs. 
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4.5 Figures 
 
Figure 4.1 Microraft based selection of cells. The microraft array in these studies is a 2.5 cm × 
2.5 cm array containing 70 × 70 microrafts. Each microraft is 200 μm × 200 μm × 200 μm in 
outer dimensions and separated from adjacent microrafts by a 100 μm gap. The cassette walls 
surrounding the array are 1 cm high allowing for excess media to be applied over the microrafts 
(A-B). Fluorescence from each microraft can be measured. In this example a “green cell” is 
identified (C). The array is encapsulated in gelatin, and the needle release mechanism pushes 
through the PDMS to release the identified microraft (D). The magnetic wand attached to the 
microscope objective captures the released microraft (E). The wand is moved to a well of a 96-
well plate where a block magnet pulls the microraft to the bottom of the well (F). A 3 × 3 
section of the array is shown using bright field microscopy (G). The needle release ejected the 
microraft in the middle. In this example 5 needle penetrations were used to demonstrate the 
accuracy of the device and to show that the elastomeric PDMS readily reseals without loss of 
media despite repeated puncturing (H). 
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Figure 4.2 Design of T cell mediated cytotoxicity assay. The microraft array was designed to 
identify the best M1p specific CTLs. The arrays were loaded with Hoechst labeled “target” 
cells (peptide pulsed DCs) at a density of 30 cells per microraft and co-incubated with CTLs 
from an M1p culture at a mean density of 1 cell per microraft. (A). Over time target cells die 
and take up Sytox Green that is present in the media (B). Microrafts with the greatest 
increase in green fluorescence are identified as likely having the most cytotoxic T cells (C). 
Both the targets and T cells distribute into the microrafts according to the Poisson 
distribution. A 5 × 5 microraft array shows multiple different ratios of cells throughout the 
array (D-E). Fluorescence images for 2 of the 4900 microrafts are shown at 1 h time points 
(images were collected every 30 min). A microraft with 1 CTL (red cell) shows increased 
killing (green fluorescence) over time (F), and another microraft without a CTL shows no 
killing over time (G). 
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Figure 4.3 M1p specific T cell culture. A T cell culture was generated against the influenza 
M1p antigen, and the percentage of M1p-specific CD8+ T cells was enumerated using 
M1p/HLA-A*02:01 tetramers and a negative control HLA-A*02:01 tetramer, along with an 
anti-CD8 antibody and a lineage marker mix of CD4, CD14, CD16 and CD19 antibodies. 
Tetramer staining was analyzed by gating on live cells (DAPI negative), lymphocytes (FSC vs 
SSC), and CD8+Lineage- cells.  Only the CD8+Lineage- cells are shown on the plots.  Over 
99% of the cells that fell in the live lymphocyte gates were CD8+Lineage-. Non-specific 
binding to the negative control tetramer was low (0.05% of CD8+ T-cells), while 48.4% of 
CD8+ T-cells had high avidity interactions with the M1p/HLA-A*02:01 tetramer (A). The 
culture also demonstrated antigen specific cytotoxicity against M1p pulsed autologous DCs 
compared to PR1 pulsed autologous DCs (B). For the cytotoxicity assay, the FSC vs SSC plot 
was gated to remove debris in the lower left hand corner, and DDAO-SE positive target cells 
(DCs) were selected on a DDAO-SE vs CMFDA plot. The percentage of dead target cells 
shown is the percentage of DDAO-SE positive DCs that also stained positive with the Fixable 
Violet Dead Cell Stain. 
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Figure 4.4 Overall analysis of cytotoxicity on microraft arrays. Two arrays are compared: the 
first with M1p-pulsed DCs as targets (A-H) and the second PR1-pulsed DCs as targets (I-P). 
The fluorescence measurements for each microraft are shown in processed 70 × 70 array 
images (A-D, I-L), where each box represents the appropriate fluorescent measurement for 1 
microraft. T cells distribute evenly across the arrays with some microrafts having 0, some 
having 1 and some having >1 CTL present, measured by enumerating the numbers of 
segmented far-red labeled cells per microraft (A, I). After 6 h, both arrays have a modest 
increase in green fluorescence (cell death) throughout the entire array (Figure 4B, J). 
Comparisons were made between the green fluorescence produced in microrafts with 0 CTLs 
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and those with 1 CTL. In these representations only microrafts with the appropriate numbers 
of CTLs (i.e. 0 or 1) are colored. Quantified green fluorescence at t = 6 h (minus green 
fluorescence at t = 0 h) for microrafts with 0 CTLs (C, K) and 1 CTL (D, L) is shown with the 
other microrafts represented in black. The differences in mean fluorescence change between 
microrafts with 0 and 1 CTL were small, but statistically significant for the M1p array (E) but 
not the PR1 array (M). The array can measure the change in green fluorescence per microraft 
during the time course of the experiment. The fluorescence over time traces for all of the 
microrafts with 0 CTLs (F, N) and 1 CTL (G, O) are shown. The microrafts with the “best 
killers” were identified as having 1 CTL with green fluorescence > 4 median absolute 
deviations above the median (denoted by the light blue bars) at all time points. There were 55 
of these microrafts on the M1p array and 8 on the PR1 array (H, P). 
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Figure 4.5 Isolation and expansion of T cells based upon cytotoxicity. The CTLs from the M1p 
array with the greatest measured cytotoxicity were sorted using the microraft release device 
into a 96-well plate and allowed to clonally expand for 2 weeks. Three clones expanded: CTL3-
MR-B8 (A-D), CTL3-MR-D10 (E-H), and CTL-MR-F9 (I-L). The t = 0 and t = 6 h 
fluorescence for each of their respective microrafts are shown (A-B, E-F, I-J). After clonal 
expansion TCR avidity for M1p/HLA-A*02:01 tetramer was measured. Negative tetramers 
were again used to define the tetramer gate (C, G, K), and all 3 clonal populations had high 
avidity interactions with M1p/HLA-A*02:01 tetramer (D, H, L). Tetramer staining was 
analyzed by gating on live cells (DAPI negative), lymphocytes (FSC vs SSC), and 
CD8+Lineage- cells.  Only the CD8+Lineage- cells are shown on the plots. 
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4.6 Tables 
Clone M1p Tetramer TCRα TCRβ 
CTL3-MR-B8 Positive V19-CALSEAGTGGSYIPTF-J6 V19-CASSMFVGQPQHF-J1-5 
CTL3-MR-D10 Positive V41-CAVSVEETSGSRLTF-J58 V19-CASSFFHNNEQFF-J2-1 
CTL3-MR-F9 Positive ND V19-CASSIRSSYEQYF-J2-7 
CTL3-LD-B2 Negative ND ND 
CTL3-LD-C4 Negative ND ND 
CTL3-LD-C8 Negative ND ND 
CTL3-LD-G3 Negative ND ND 
 
Table 4.1 Expanded T cell clones. Seven T-cell clones were expanded using either microraft 
selection (denoted -MR-) or limiting dilution (denoted -LD-). Three of 3 MR selected clones 
expressed high avidity TCRs towards M1p/HLA-A*02:01 tetramer. The V segment, CDR3 
sequence, and J segment for both the TCRα and TCRβ chain were sequenced on the first 2 
clones, but only the TCRβ sequence could be determined for the third clone. None of the clones 
identified by LD expressed high avidity TCRs. Therefore, their TCRs were not sequenced. 
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